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ABSTRACT 
SOXC transcription factors are key transcriptional regulators that have been shown 
to control self-renewal and differentiation in tissues during development in vivo, but 
have not been studied in the mammalian kidney. Our lab has previously demonstrated 
that all three members of the SoxC genes family, namely, Sox4, Sox11 and Sox12, are 
co-expressed with the Wilms’ Tumor Suppressor-1 (Wt1) gene, which is known to be 
essential in nephron progenitor cells during the early stages of kidney development. We 
have also demonstrated an essential role for at least one member of the SoxC subfamily, 
Sox4, during renal development in vivo. As a first step towards identifying potential 
SOXC co-factors during embryonic kidney development, I compiled a comprehensive 
list of all proteins shown to interact with SOX family members to regulate transcription 
in vitro. The list was then expanded to include highly homologous members of the same 
family or subfamily. Next, reverse transcription (RT)-PCR and quantitative real-time (q) 
PCR was performed for candidate partner genes at multiple time points of renal 
development. Candidate SOXC partner genes that exhibited strong renal developmental 
expression patterns included members of the Dlx, Pou, Pax, Ube, and Med families of 
transcription factors. Results from this work lay the foundation to elucidate the 
molecular mechanisms by which SOXC proteins regulate transcription during renal 
development in vivo. Future experiments will include cross-linking protein interaction 
analyses and pull-down assays to identify protein-protein interactions in vitro.  
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1. INTRODUCTION 
 
1.1 Kidneys  
 The kidneys are major organs of the urinary system. The vertebrate urinary system 
consists of two kidneys, two ureters, the bladder and the urethra. The urinary system 
performs essential functions to regulate both the volume and composition of body fluids 
as well as the elimination of metabolic waste products (Davidson et al., 2008; Little and 
McMahon, 2012). 
 
1.1.1 Kidney structure and functions  
The kidney is composed of a capsule, cortex and medulla. The renal capsule is a 
fibrous outer layer, the cortex is the peripheral layer and the medulla is the inner layer. 
Kidney shape differs among species. The human kidney has a typical multilobar form. 
The medulla of the human kidney contains multiple pyramidal structures. The apex or 
papilla of each pyramid is directed toward the renal pelvis. A medullary pyramid 
together with overlying cortex forms a renal lobe (Davidson et al., 2008) (Fig.1). 
Common laboratory animals such as rats and mice, as well as dogs, cats, horses, sheep 
!*!
and goats have unilobar (unipapillary) kidneys, with the cortex and medulla fused into a 
single renal papilla (Eurell and Frappier, 2006). In all forms of kidney, urine drains from 
the papilla into the renal pelvis and from the renal pelvis to the bladder via the ureter. 
The functional units of the kidney are nephrons that are found within the medulla and 
cortex. A human kidney is comprised 200,000 to 1.8 million nephrons (Little and 
McMahon, 2012). The nephron is composed of a renal corpuscle composed of a 
glomerulus enclosed in a Bowman’s capsule, proximal convoluted tubule, loop of Henle, 
and distal convoluted tubule. At the proximal end of the nephron, blood is filtered 
through the glomerular filtration barrier and the filtrate passes into the tubular nephron, 
which modifies the filtrate before delivering the urine to the collecting duct for disposal 
into the renal pelvis (Davidson et al., 2008).   
       The kidney participates in elimination of body waste, regulation of water and 
electrolyte balance, regulation of arterial blood pressure, regulation of acid-base balance, 
regulation of erythropoiesis, regulation of vitamin D synthesis and regulation of glucose 
synthesis (Guyton and Hall, 2006).!
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 Figure 1. Structure of the human kidney (Modified from Davidson et al., 2008) 
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1.2 Kidney development  
 
       Development of the mammalian kidney is distinct from that of most other 
organs, proceeding through the formation of transitory kidney systems including the 
pronephros and mesonephros before forming the permanent functional kidney, the 
metanephros (Gilbert, 2010). The kidneys develop in a cranial to caudal direction within 
the intermediate mesoderm located between the paraxial mesoderm and lateral plate 
mesoderm in association with the nephric ducts (Chai et al., 2013). The first kidney to 
develop is the pronephros. The pronephros is not a functional kidney and quickly 
degenerates. The mesonephros begins development caudal to the pronephros. The 
mesonephros consists of glomeruli and mesonephric tubules that open into the 
mesonephric duct, a continuation of the nephric duct. The mesonephros also degenerates 
but tubules and ducts have derivatives in adult animals (Dressler, 2009). The 
metanephros (permanent kidneys) begins to form from the ureteric bud (UB), an 
outgrowth from the Wolffian duct, and the metanephric mesenchyme (MM).   The 
metanephric kidneys are functional in the fetus (Chai et al., 2013).   
 
1.2.1 Mouse metanephric kidney development 
     The development of kidneys in the mouse begins with the formation of the 
nephric duct (mesonephric/Wolffian duct) from the intermediate mesoderm and grows 
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caudally (Davidson et al., 2008) (Fig.2). The formation of mesonephric nephrons is 
induced by the Wolffian duct in the adjacent intermediate mesoderm (nephrogenic cord). 
The development of mouse metanephros begins at the caudal end of the nephric duct and 
nephrogenic cord.  
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Figure 2. Overview of mouse kidney development at embryonic days 8.5, 9.0, 10.5 
and 11.5 (E8.5, E9.0, E10.5 and E11.5 respectively) (Modified from Davidson et al., 
2008). 
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1.2.2 Pronephros  
 The pronephros is the most primitive kidney. It is present only in the embryonic 
stage and is non-functional (Wessely and Tran, 2011). In the mouse, the pronephros is 
hardly detectable while mesonephric tubules are well developed (Dressler, 2009). The 
mouse pronephros develops from the intermediate mesoderm at embryonic day (E) 8.0 
(Bouchard et al., 2000), at the level of presumptive somites 5-8. At that time, precursors 
of the pronephric duct separate away from the intermediate mesoderm in this region to 
form a short, caudally growing longitudinal rod of cells. Cells of the longitudinal rod 
undergo a mesenchymal-to-epithelial transition (MET) to generate the epithelial lined 
pronephric duct (Davidson et al., 2008) (Fig. 2). After formation, the cranial portion of 
the nephric duct degenerates by apoptosis. The duct persists in the more caudal part of 
the duct persists in the formation of the mesonephros and metanephros (Pole et al., 2002; 
Pietila and Vainio, 2005). In addition, some genes in the persisted duct are important for 
the subsequent development of the mesonephros and metanephros (Chai et al., 2013). 
 
1.2.3 Mesonephros 
The mesonephros forms in all vertebrates but degenerates in higher vertebrates 
such as mice and humans (Wessely and Tran, 2011). The mouse mesonephros develops 
along the caudal portion of nephric duct as the pronephros degenetrates at E10 (Dressler, 
2009; Rumballe et al., 2010). The mouse mesonephros is composed of approximately 18 
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pairs of tubules, which extend from the somite level 10 to 17. The mesonephros is 
divided into distinct cranial and caudal sets of tubules (Sainio, 2003) (Fig. 2). The 
cranial set develops rudimentary branched tubules that join with the nephric duct at 4–6 
sites (Sainio et al., 1997). Since the cranial mesonephros keeps contact with the 
Wolffian duct during the kidney development, it is believed that the cranial set of 
mesonephros is formed from the Wolffian duct (Joseph et al., 2009). In contrast, the 
caudal set of tubules make up the bulk of the mesonephros, and they are composed of 
primitive unbranched tubules that do not connect to the Wolffian duct. They are believed 
to be derived from the nephrogenic cord (Joseph et al., 2009). These unbranched tubules 
first appear as condensations of nephrogenic cord cells at the somites level 8-9 at E9 
(Vetter and Gibley, 1966; Rumballe et al., 2010). These condensed cells undergo a MET 
to form a renal vesicle and then elongate into an S-shaped body (Dressler, 2009). At 
E14.5, the mesonephros begins to degenerate and within 24 hours, almost all of the 
tubules undergo apoptosis and disappear following in a caudal to cranial direction 
(Sainio et al., 1997; Little and McMahon, 2012). Eventually all glomeruli degenerate 
while the mesonephros disappears. However, some of the tubules persist in both sexes. 
In the male, the cranial tubules become the efferent ductules of the testis. In the female, 
the mesonephric tubules associated with the cranial and caudal part of the duct persist as 
residual structures in the mesosalpinx that is a part of the abdominal cavity from the 
ovary to the level of the uterine tube (Eurell and Frappier, 2006). 
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1.2.4 Metanephros  
      The metanephros, the permanent kidney, begins to develop when an outgrowth 
of the Wolffian duct grows into the surrounding metanephric mesenchyme (Fig. 2). This 
outgrowth is termed the ureteric bud. The ureteric bud epithelium invades the 
metanephric mesenchyme and begins to undergo branching morphogenesis (Chai et al., 
2013). Some mesenchymal cells condense around the tips of newly formed branches to 
form nephron progenitor cells (NPC). The NPCs begin to undergo the process of MET 
under the inductive signal from the ureteric bud tips (Fig. 3). At the same time, other 
loose mesenchymal cells generate the interstitial stroma (Davidson et al., 2008). NPCs 
first form a polarized renal vesicle with one end of the vesicle retaining in contact with 
the ureteric bud epithelium. Then, a single cleft forms in the renal vesicle to generate a 
comma shaped body. A second cleft generates the S-shaped body. At this point, the 
S-shaped body has already patterned along a proximal-distal axis (Dressler, 2006). The 
S-shaped body is organized into three components: the distal, medial and proximal 
segments (Georgas et al., 2009). The distal end of the S-shaped body fuses with the 
ureteric bud epithelium to form a single, continuous epithelial tubule. At the proximal 
end, as endothelial cells invade the more proximal cleft, the S-shaped body forms the 
Bowman’s capsule around the glomerular tuft (Quaggin and Kreidberg, 2008). Signaling 
interactions between mesenchymal derived epithelial cells of Bowman’s capsule and 
endothelial cells lead to the formation of the glomerular basement membrane (GBM), 
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which is a highly specialized matrix that forms the scaffold for the filtration barrier 
(Chai et al., 2013). At the most proximal end are the precursor cells of the podocytes 
(Dressler, 2009).  
The renal corpuscle containing the glomerulus is the most proximal part of the 
nephron, and it is an intricate structure, which includes a filtration barrier (Fig. 4). The 
glomerulus is a highly developed vascular bed that functions in filtration (Quaggin and 
Kreidberg, 2008). A mature glomerulus is composed of two distinct types of cells; 
endothelial cells and mesangial cells. The capillary endothelial cells form a fenestrated 
capillary tuft, which can allow proteins and fluid to pass through the endothelial wall 
(Quaggin and Kreidberg, 2008; Dressler, 2009). Mesangial cells are able to provide 
structure and elasticity to the capillary tuft, secrete extracellular matrix, and act as 
specialized pericytes to dilate or constrict capillaries thereby regulating blood flow 
(Fogo and Kon, 2010). The GBM separates the endothelial and mesangial cells from the 
urinary space. The GBM is a specialized basement membrane that is covered by the 
visceral epithelial cells of Bowman’s capsule, the podocytes, whose extending foot 
processes interdigitate to create filtration slits, and a unique type of membrane, the slit 
diaphragm (Dressler, 2006; Quaggin and Kreidberg, 2008). The slit diaphragm separates 
the GBM from the urinary space (Dressler, 2009) and is involved in maintaining normal 
renal function by regulating a specific pore size such that only molecules smaller than 
approximately 5000 daltons can traverse the filtration barrier and enter the urinary space 
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(Quaggin and Kreidberg, 2008; Fogo and Kon, 2010). Therefore, damage to the slit 
diaphragm will lead to renal diseases (Quaggin and Kreidberg, 2008). The urinary space 
is surrounded by the parietal epithelium of Bowman’s capsule and exits into the 
proximal convoluted tubule (Dressler, 2009).  
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Figure 3. Sequential steps of nephrogenesis (Modified from Dressler, 2006). 
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Figure 4. The sequential stages of glomerular development (Modified from 
Dressler, 2006). 
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1.2.5 Ureteric bud branching 
        In mammals, kidney development begins with an outgrowth at the posterior 
end of the Wolffian duct (at 5 weeks of gestation in the human and E10.5 in the mouse) 
(Chai et al., 2013). This outgrowth forms a simple epithelial tube called the ureteric bud 
which subsequently elongates and invades the surrounding metanephric mesenchyme. 
The part of the ureteric bud that invades the metanephric mesenchyme consists of a stalk 
and tip. The tip forms a swollen and rounder structure called the ampulla (Bridgewater 
and Rosenblum, 2009) (Fig. 5a). Under the inductive signal from the NPCs; the ampulla 
then divides to form two new ampullae, each of them will form a new branch (Fig. 5b). 
Tip-cell proliferation is thought to contribute to the formation of the next generation of 
tips and the lengthening of growing stalks (Bridgewater and Rosenblum, 2009). As 
organogenesis comes to completion, the UB branching slows down, presumably owing 
to negative feedback and finally forms the collecting ducts of the kidney. Abnormalities 
in the ureteric branch pattern can lead to renal malformations, including renal agenesis, 
renal dysplasia, and cystic abnormalities as well as alterations in nephron number 
(Costantini, 2010).  
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Figure 5. UB branching. (A–B) Schematic diagrams of branching events and images of 
cultured kidneys isolated from a Hoxb.7GFP transgenic mouse where green fluorescent 
protein (GFP) fluorescence marks the UB and its derivatives. (Modified from 
Bridgewater and Rosenblum, 2009) 
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1.3 Wilms’ Tumor Suppressor 1(WT1) 
 
        Renal dysplasia is a common cause of young children’s end-stage renal failure. 
It is characterized by abnormal cellular differentiation during renal development leading 
to tubular malformation. The congenital human kidney diseases Frasier Syndrome, 
Wilms tumor, aniridia, genitourinary anomalies, and mental retardation (WAGR) 
Syndrome, and Denys Drash Syndrome are all characterized by renal dysplasia, and are 
causally linked to mutations in the Wilms’ Tumour Suppressor-1 (WT1) gene. 
 
 
1.3.1 Kidney diseases  
 
        Congenital anomalies of the kidney and urinary tract (CAKUT): CAKUT is the 
most common cause of childhood end-stage renal disease, and comprise approximately 
30% of all prenatally diagnosed malformations. CAKUT are variable in phenotype and 
can affect the kidney alone or involve the lower urinary tract. Congenital renal 
anomalies can be familial or sporadic familial, syndromic, or nonsyndromic. For the 
syndromic forms of congenital renal anomalies, genetic causes have been identified and 
have been investigated (Toka et al., 2010). 
 
        Denys-Drash Syndrome (DDS): Denys-Drash Syndrome is a relatively rare 
congenital childhood syndrome. DDS includes diffuse severe hypertension, progressive 
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glomerulopathy, a steroid-resistant nephrotic syndrome, and genital abnormalities. This 
syndrome rapidly progresses to end-stage renal disease before the age of five and bears a 
high risk of developing Wilms’ tumor (Denys et al., 1967; Schumacher et al., 2006). The 
life-saving treatment of DDS is kidney transplantation and early bilateral nephrectomy 
before the development of Wilms’ tumor (Mrowka and Schedl, 2000). Denys-Drash 
Syndrome is associated with WT1 mutations of missense mutations in the zinc-finger 
region (Little et al., 2005) 
 
         Frasier Syndrome (FS): Frasier Syndrome is a slowly progressing nephrotic 
syndrome, which is attributable to focal segmental glomerulosclerosis. This is a high 
risk of development of end stage renal failure and complete male to female gender 
reversal but there is no development of Wilms’ tumor (Frasier, 1964; Kitsiou-Tzeli et al., 
2012). To date, WT1 mutations have been found in many patients with Frasier syndrome. 
The WT1 mutations are caused by mutations of the alternative splicing donor site in 
intron 9 (Zugor et al., 2006). In contrast to DDS, end-stage kidney disease develops 
more slowly and at a later stage in life (Mrowka and Schedl, 2000). 
 
1.3.2 Wilms’ Tumor 
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        Wilms’ tumor is the second most common intraabdominal cancer of 
childhood and the fifth most common pediatric malignancy. Approximately 6% of all 
pediatric cancers are Wilms’ tumors and more than 95% of all kidney tumors in the 
pediatric age group are Wilms’ tumors (Breslow et al., 1993; Pastore et al., 2006). In the 
United States there are approximately eight cases of Wilms’ tumor per million children 
less than 20 years of age per year, with the total number of new cases being estimated at 
about 500 cases per year. Wilm’s tumor occurs most commonly among children younger 
than five (Smith et al., 2010).  
  Wilms’ tumor is an embryonic renal neoplasm that contains blastemal, stromal, 
and epithelial cells in varying proportions (Kim and Chung, 2006; Melchionda et al., 
2013). There are various congenital anomalies known to associate with Wilms' tumor. 
Those anomalies include aniridia, hemihypertrophy, genitourinary tract anomalies such 
as cryptorchidism and hypospadias, DDS, and Beckwith-Wiedemann syndrome. These 
anomalies confer an increased risk of the development of Wilms’ tumor (Kim and 
Chung, 2006). Wilm’s tumor can be divided into three prognostic subgroups: low-risk 
tumors, the intermediate-risk group of tumors and the high-risk group tumors (Stewenius 
et al., 2007). Wilm’s tumor also is believed to have a substantial heritable fraction since 
the tumor can be bilateral, and associated with congenital anomalies (Melchionda et al., 
2013).  
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   The formation of Wilms’ tumor is complex, involving multiple genes and 
genetic events. Based on a number of studies, mutations in WT1 are believed to be 
involved in the development of Wilms’ tumor. One hundred percent of DDS patients 
were found to have WT1 gene deletions or mutations (Rauscher, 1993; Kitsiou-Tzeli et 
al., 2012). The WT1 gene encodes a transcription factor, which is critical to normal 
kidney and gonadal development. The exact role of WT1 in tumor suppression remains 
unknown (Melchionda et al., 2013).  
 
1.3.3 WT1  
        The human WT1 gene is located on chromosome 11 and spans approximately 
50 kb and includes 10 exons that generate a 3-kb mRNA (Call et al., 1990; Gessler et al., 
1990; Chau and Hastie, 2012). There are four zinc finger motifs in the carboxyl-terminal 
portion of the WT1 DNA- binding domain, and they all share homology with the early 
growth response gene 1(EGR1) family. This suggests that the WT1 protein has a role as 
a transcription factor (Chau and Hastie, 2012). It has been shown that WT1 can bind to 
the promoter regions of downstream target genes. WT1 can either repress or activate the 
target gene (Sharma et al., 1992; Hartwig et al., 2010).  
        During embryogenesis, the expression pattern of WT1 is highly complex 
(Mrowka and Schedl, 2000). For example, Wt1 transcripts were found expressed at the 
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NPC during renal development in mice (Kreidberg, 2010). However, the expression of 
Wt1 is weak during the condensation of the metanephric mesenchyme, and the 
expression of Wt1 dramatically increases during the MET in the NPCs lineage (Mrowka 
and Schedl, 2000). Wt1 expression is highest in the most proximal portion of the 
S-shaped body that flattens to form the podocytes. It has been reported that WT1 activity 
is essential for the transition of cells from mesenchymal and epithelial cell states (Chau 
and Hastie, 2012). Cells such as podocytes with the potential of epithelial to 
mesenchymal transition have been found to have Wt1 expression (Grubb et al., 1994; 
Kreidberg, 2010). In the adult kidney, Wt1 expression can be found in the podocytes, 
and the expression can be seen at a very lower level in parietal epithelial cells of 
Bowman’s capsule (Chau and Hastie, 2012). In addition to the kidney, Wt1 is also 
expressed has an expression in the spleen (Herzer et al., 1999; Hartkamp et al., 2008), 
the mesothelium, and the genital ridges, which develop into testes or ovaries depending 
on the presence or absence of the Y chromosome (Nachtigal et al., 1998; Barrionuevo et 
al., 2012). 
    The complexity of Wt1 expression suggests that WT1 is required at multiple 
stages during kidney development. In Wt1 knockout mice, the outgrowth of ureteric bud 
is terminated and the metanephric blastema undergoes apoptosis (Kreidberg, 2010). 
Apoptosis was not terminated even when blastema from knockout mouse was 
recombined with ureteric buds from wild-type mouse during organ culture experiments. 
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These data suggest that Wt1 has at least two functional roles during the initial part of the 
kidney development (Mrowka and Schedl, 2000). Wt1 may be required for the inductive 
signaling, which induces the outgrowth of the ureteric bud, or it may be involved in 
either survival or the reception of the survival signal from the ureteric bud (Mrowka and 
Schedl, 2000; Kreidberg, 2010). 
    Therefore, identifying the direct target genes of WT1 will be essential for 
understanding the function of WT1 in developing organs including the developing 
kidney. From ChIP-Chip analysis, essential kidney development genes, such as Pax2, 
Bmp7 and Sall1 were identified as WT1 transcriptional targets, and all three members of 
the Sry-related high mobility group (HMG) Box (Sox)-C subfamily - Sox4, Sox11 and 
Sox12- have also been identified as WT1 gene targets by ChIP-Chip (Hartwig et al., 
2010).  
   
1.4 SOX transcription factors  
1.4.1 SOX family 
        SOX genes and their proteins belong to the high mobility group (HMG) 
superfamily, which consists of two subfamilies: the SOX family and the T-cell factor 
(TCF)/lymphoid enhancer binding factor (LEF-1) family (Laudet et al., 1993; 
Grosschedl et al., 1994; Soullier et al., 1999; Zhu et al., 2012). The male sex 
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determination gene Sry (sex-determining region Y) was the first-identified member of 
the SOX gene family (Koopman, 1999; Castillo and Sanchez-Cespedes, 2012). SOX 
proteins can bind specific DNA sequences. For example, SOX proteins bind the minor 
groove of DNA and bend it at an angle. This change of conformation may bring distal 
proteins on gene promoters closer together, allowing them to functionally interact. As a 
result, SOX proteins are regarded as developmental transcription factors (Kamachi et al., 
2000; Kondoh and Kamachi, 2010).  
  SOX proteins can be identified based on a conserved motif within the HMG 
domain, RPMNAFMVW (Bowles et al., 2000; Kiefer, 2007). However, an intriguing 
exception is that the first characterized SOX protein, SRY protein, bears only RPMNAF. 
For proteins, a sequence motif is formed by the three dimensional arrangement of the 
amino acids and it has biological significance. Based on the phylogenic analysis of their 
HMG domains, SOX genes are separated into eight groups, A-H, including (SOXA: Sry), 
(SOXB: SOX1, SOX2, SOX3, SOX14, SOX21), (SOXC: SOX4, SOX11, SOX12), (SOXD: 
SOX5, SOX6, SOX13), (SOXE: SOX8, SOX9, SOX10), (SOXF: SOX7, SOX17, SOX18), 
(SOXG: SOX15) and (SOXH: SOX30) (Bowles et al., 2000; Kondoh and Kamachi, 
2010).   
  The functions of SOX proteins include regulation, specification, and 
differentiation of many cell types, such as chondrocytes and the Sertoli cells of the 
developing testes. Proteins resulting from genes within the same group share functional 
roles and can counteract the functions of other groups. In addition, the same protein can 
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mediate different stages of development in one cell type or more. One possible answer to 
the question of why several SOX genes exist within each group is that they may provide 
a safety mechanism (Kiefer, 2007). If one SOX protein encoded by one SOX gene is 
malfunctioning, there would be always another protein within the same group to help 
instead. Kidney development is regulated by signal pathways at a molecular level such 
as the SOX transcription factors (proteins). These perform a variety of crucial roles in 
vertebrate development by activating or repressing specific target genes through 
interaction with different proteins (Uwanogho et al., 1995; Collignon et al., 1996; 
Kreidberg, 2010). It has been proposed that SOX proteins paired with protein partners 
have a significant role in the regulation of the embryonic development and the 
determinations of the fates of cell (Kamachi et al., 2000; Kondoh and Kamachi, 2010).    
    SOX genes have been found in all bilaterian metazoans, which is evidence that 
a full complement of the major groups of the SOX gene family was already established 
early in the evolution of the Bilateria (Bowles et al., 2000; Castillo and 
Sanchez-Cespedes, 2012). However, there is a dramatic difference in the number of SOX 
genes between the protostomes and the deuterostomes. Model protostomes such as the 
Caenorhabditis elegans worm (nematode) have few SOX genes, with numbers ranging 
between five and eight, while deuterostomes, such as mammals, have as many as 20 
SOX genes which can then be separated into the above groups and further into subgroups 
(Bowles et al., 2000; Castillo and Sanchez-Cespedes, 2012). For example, the five SOXB 
genes found in deuterostomes can be further separated into SOXB1 and SOXB2 
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subgroups (Bowles et al., 2000; Kiefer, 2007).   
         
1.4.2 SOXC subfamily: SOX4, SOX11 and SOX12 
    
     Based on phylogenic study, the SOXC subfamily consists of three highly 
homologous proteins, SOX4, SOX11 and SOX12 (Dy et al., 2008). These proteins show 
similar DNA-binding properties and transcription potentials. All SOXC proteins are 
widely and dynamically expressed during mouse embryogenesis. For example, it has 
been shown that Sox4 and Sox11 genes regulate the late steps of neural development 
(Bergsland et al., 2006). In addition, SOXC genes can directly activate early genes, 
which can give cells general neuronal properties. This is necessary for cell type-specific 
differentiation. The SOX11 gene plays a role in cardiogenesis, regulating outflow tract 
formation, development of multiple organs (lung, stomach, pancreas, spleen, eye and 
skeleton), and pan neuronal gene activation during neuronal maturation (Schilham et al., 
1996; Hargrave et al., 1997; Kuhlbrodt et al., 1998a; Zhu et al., 2012). In conclusion, 
SOX4 and SOX11 genes have significant roles in developmental processes, but their 
molecular roles in many lineages and the roles of SOX12 gene remain largely unknown.   
A recent study has shown that all three members of the SOXC subfamily are 
expressed in nephron progenitor cells, ureteric bud tips and forming nephrons in 
developing mouse kidney (Huang et al., 2013). In addition, the conditional knock out of 
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Sox4 in NPC leads to the reduction of nephron numbers and malformation of podocytes 
during mouse renal development (Huang et al., 2013). These all suggest that SOXC 
transcription factors may play essential roles in mouse nephrogenesis.  
1.5 Protein partners of SOXC transcription factors  
 
        It has been shown that SOX proteins often pair off with specific protein 
partners to regulate gene transcription (see Table 1 in Results). This mechanism allows 
SOX proteins to initiate a sharp transition in the set of regulated genes, probably either 
in accordance with the change of the partner factor or due to dynamism of the expression 
of the SOX (Kondoh and Kamachi, 2010). 
 
1.5.1 SOX protein partners 
 
        Several SOX factors are expressed in more than one cell type, and they 
regulate different events in the same cell type. For instance, SOX9 is expressed in 
developing chondrocytes and also in Sertoli cells of developing testis. SOX18 is 
expressed in developing vascular endothelial cells and in mesenchymal cells subjacent to 
invaginating hair and feather follicles (Bernard and Harley, 2010). All SOX protein 
factors recognize a similar DNA-binding motif (A/TA/TCAA A/TG). Certain SOX 
factors are present in several different types of cells and those cells can express several 
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different kinds of SOX proteins. Therefore, the question arises, how does each SOX 
factor recognize its target gene? 
        Target gene specificity or regulation is achieved by binding with specific 
protein partners in order to direct gene expression for a particular cell type. Regulated 
genes have binding sites for both SOX proteins and their partner proteins on their 
enhancer sequences (Kondoh and Kamachi, 2010). Accumulated evidence shows that 
SOX proteins form multi-protein complexes at gene promoter or enhancer sites, and that 
these complexes enable stable DNA binding, SOX gene specificity and activation of SOX 
gene. Based on these studies, Kamachi et al. (2000) proposed a model suggesting that 
binding of the SOX transcription factor to its site on the gene enhancers is not sufficient 
to exert its regulatory function because SOX proteins, in most cases, bind to DNA with a 
dissociation constant of 10-8 - 10-9 M in vitro, which might not be stable enough to exert 
transactivation in vivo. On the other hand, abundant protein activators bind to DNA with 
a dissociation constant of 10-11 M in vitro. Because of this low DNA binding affinity of 
SOX protein, assistance of a co-DNA-binding partner factor might result in the 
achievement of stable binding and successful activation of the gene in vivo. This model 
also sheds light on how valuable SOX-partner pairing is and how the pairing increases 
the strength and stability with which SOX transcription factors bind to their respective 
proteins (Kondoh and Kamachi, 2010). For example, SOX2 is important for lens 
development, and it can bind to !-crystallin gene minimal enhancer, DC5, which directs 
lens-specific gene expression. This binding requires a partner factor called "EF3 
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(Kamachi et al., 2000). SOX9 is important for cartilage and genital ridge formation by 
activation of its target gene Col2a1, which encodes type II collagen. This binding 
requires a partner protein COL2C2 (Kondoh and Kamachi, 2010).  
        In an in vivo situation where DNA is in a chromatin structure, the HMG 
domain of SOX is not sufficient to form a stable protein–DNA complex at a SOX site, 
although its DNA binding is demonstrable in vitro (Kondoh and Kamachi, 2010) (Fig. 
6a). A SOX protein forms a stable complex with the target DNA only in the presence of 
a partner factor, which interacts with the SOX protein and binds to a nearby DNA site. 
Transcriptional activation or repression by a SOX protein is achieved only under this 
condition (Fig. 6b). The partner factor at a SOX-binding site of an enhancer is 
determined by two conditions: first, the availability of the binding site for a partner 
factor in a proper location and orientation; and second, the availability of the partner 
factor in the cell (Fig. 6c). 
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1.5.2 SOXC protein partners 
    SOXC proteins interact with protein partners to regulate gene expression. The 
three SOXC proteins have conserved, overlapping expression patterns and have similar 
molecular properties. These might therefore act in concert to fulfill essential roles in vivo. 
The SOX4 protein encoded by the SOX4 gene can interact with syntenin (PDZ protein) 
in B cells, but how the genes are regulated is not yet known (Geijsen et al., 2001). 
SOX11 protein can interact with Brn-1 (a member of POU protein family) in glial cells, 
but how the genes are regulated is also not yet determined (Kuhlbrodt et al., 1998a). All 
SOX transcription factors can recognize a similar core DNA binding motif. Each of the 
SOX transcription factors can be expressed in a variety of cellular contexts, and a given 
cell type can co-express a number of SOX factors. The specificity of the interaction 
between a certain SOX transcription factor with the target gene is determined by the 
protein partners (Kondoh and Kamachi, 2010). Identifying which protein partners 
interact with SOXC transcription factors is the key to understanding the roles of SoxC 
genes in renal development since SOXC transcription factors need the specific protein 
partners to maintain the specificities during the renal development.  
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1.6 Research objectives  
1.6.1 Rationale 
SOX transcription factors play master regulatory roles in a multitude of 
developmental processes, including stemness, male differentiation, chondrogenesis, 
neurogenesis and gliogenesis, as well as development of the neural crest, spinal cord 
and heart (Bowles et al., 2000). However, their function in the developing kidney is 
largely undefined. All SOX proteins recognize a similar core DNA binding motif, 
and a given cell type can co-express a number of SOX factors. Despite weak DNA 
binding specificities, individual SOX proteins recognize different target genes. 
Target gene specificity is thought to be attributable in part, to the formation of 
multi-protein complexes comprised of a SOX protein and cell-specific cofactors at 
gene promoters or enhancers. To date, only a limited number of Sox protein partners 
have been identified. We have recently demonstrated that all three highly-related 
members of the SoxC subfamily are strongly expressed in nephron progenitor cells 
and their derivative nephrogenic structures during renal development. We have also 
demonstrated an essential role for Sox4 during renal development in vivo (Huang et 
al., 2013). Identifying SOXC protein partners during kidney development will help 
us to comprehensively understand the SOXC regulatory network during the kidney 
development. 
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1.6.2 Hypotheses  
In this study, the following hypotheses were tested: 
            1. There are highly homologous members of SOX protein partners. 
2. Potential protein partners of SOXC transcription factors are highly 
expressed during mouse kidney development. 
3. Potential protein partners of SOXC transcription factors share a similar 
mRNA expression pattern as SOXC subfamily. 
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2. MATERIALS AND METHODS 
 
2.1  Tissue isolation 
  CD-1 embryonic and adult mice (Mus musculus) provided by the Atlantic 
Veterinary College, UPEI were used in this study. All experiments were carried out in 
accordance with the UPEI Animal Care Committee guidelines. Wild type mice were 
paired overnight. The detection of a vaginal plug the next morning staged the embryos 
as embryonic (E) 0.5 days old. Three litters each of E12.5, E13.5, E14.5, and E18.5 day 
embryos from 3 different female wild type mice and 3 each of postnatal (P) 7 day and 
P21 day (adult) mice were dissected and kidneys collected. Kidneys from different litters 
were separated in RNA latertm on ice and stored in -80oC until RNA isolation was 
performed. 
 
2.2 RNA isolation and reverse transcription  
      Separated tissues were homogenized by a Rotor stator with #-mercaptoethanol. 
Tissue lysates were applied to RNA isolation by using an Illustra™ RNAspin Mini RNA 
Isolation Kit (GE Healthcare Inc). All of the steps were carried out on ice following the 
manufacturer’s instructions except that the total RNA was eluted with 200µl nuclease 
free H2O (GIBCO Inc). The steps in order are: 1) homogenization of kidney tissues 
!,,!
using the Rotor Stator, 2) cell lysis, 3) filtration of the lysate, 4) adjustment of RNA 
binding conditions, 5) binding of the RNA, 6) desalting of the silica membrane: This 
prepares favourable conditions for DNA digesting by DNases because salt removal 
makes the subsequent DNase digest much more effective, 7) digesting DNA: Since DNA 
and RNA bind to the silica membrane, DNases to thoroughly digest DNA, 8) washing 
and drying the silica membrane, 9) eluting highly pure RNA. The detailed protocol can 
be found in the Appendices.  
     The quality and concentration of total RNA were measured by using NanoDrop 
ND-1000 spectrophotometer (Thermo Inc.) and agarose gel electrophoresis. All samples 
had concentrations of 100- 300 ng/µl, a 260/280 ratio of 1.8-2.2, a 260/230 ratio above 
1.8 and two clear bands of 28S and 18S RNA by gel electrophoresis. 
The mRNA was reverse transcribed into cDNA using the Quanta qScript supermix 
cDNA synthesis kit (Quanta Inc). A mixture of 4µl of 5x super mix, 1µg of RNA 
template and a total reaction volume of 20µl with nuclease free H2O was incubated for 5 
minutes at 25oC followed by 30 minutes at 42 oC and 5 minutes at 85oC. cDNA was 
diluted 20x in nuclease free H2O and stored at -40
oC for RT-PCR. After cDNA synthesis, 
cDNA purity was tested by agarose gel electrophoresis. To test the quality of the cDNA, 
the primer for the house keeping gene Gapdh and the primer for Six2 were used. High 
quality cDNA should show the same bands width in each stage in the agarose gel 
analysis. The Six2 gene is a marker of NPC and usually expressed in early embryonic 
development such as the E13.5 stage. It is expressed at lower levels in the E18.5 stages  
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Table 1. mRNA concentration (ng/µl) of four biological replicates of mouse kidney 
tissues at E13.5, E18.5 and P21 for RT-PCR.  
 
Biological Replicate 
mRNA  Concentration (ng/µl) 
E13.5 E18.5 P21 
1 172.9 299.2 146.2 
2 206.1 615.6 398.0 
3 141.1 538.2 376.3 
4 158.0 691.1 448.4 
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Table 2. mRNA concentration (ng/µl) of four biological replicates of mouse kidney 
tissues at E12.5, E14.5, E18.5, P7 and P21 for Real-time PCR. 
 
Biological Replicate 
mRNA  Concentration (ng/µl) 
E12.5 E14.5 E18.5 P7 P21 
1 106.4 218.0 540.0 117.1 376.2 
2 127.1 150.0 617.0 119.0 448.0 
3 130.8 218.0 771.3 114.0 89.6 
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and minimally expressed in adults; therefore, the Six2 bandwidth in high quality cDNA 
from E13.5 samples should be almost double compared to that in E18.5 stage samples 
(Fogelgren et al., 2009). In addition, the bandwidth in adults should be negligible 
(Fig.7). 
        The following RT-PCR and real-time PCR identified the expression level of 
each gene based on the cDNA template. Therefore, to have precise comparison of the 
expression level of each gene, the exact same amount of RNA should be added during 
the cDNA synthesis. 
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Figure 7. Gapdh and Six2 gene expression on four biological replicates of mouse      
kidney cDNA at E13.5, E18.5 and P21. Biological replicate 1(Bio 1), 
Biological replicate 2(Bio 2), Biological replicate 3(Bio 3), Biological 
replicate 4(Bio 4). 
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2.3 Primer design and Reverse Transcription (RT)-PCR  
I first sought to list all genes reported to interact with members of the SOX gene 
family. The list of genes was treated as potential SOXC partners. The NCBI PubMed 
database was chosen as the main resource used to search for previously published 
articles on the SOX gene family and their interactions with other proteins.  
Primers were designed using PrimerBank 
(http://pga.mgh.harvard.edu/primerbank/), and selected primers were confirmed for 
sequence specificity by NCBI BLAST (http://blast.ncbi.nlm.nih.gov/). Primer lengths of 
18-24 base pair (bp) were chosen for both forward and reverse primers and the amplicon 
sizes of 100-200 bp were chosen to maximize amplification efficiency overlapping 
intron-exon boundaries. Primers were purchased from Sigma Aldrich. 
  RT-PCR was used to show whether specific genes were expressed in four 
biological replicates of cDNA obtained from murine kidneys at E13.5, E18.5 and P21. 
The PCR was carried out using Econotaq MasteMix (Lucigen Inc). PCR conditions were 
optimized to show specific bands. Gapdh and Six2 were used as the positive controls. 
Agarose gel electrophoresis was conducted after RT-PCR. Ethidium bromide was used 
as the fluorescent marker. The gel electrophoresis images were analyzed by the image 
software Gel Analyzer (Lazar software Inc). Every candidate partner’s gel band pixel 
intensity was measured using this software. The fold change of pixel intensity at E13.5 
!,(!
compared to P21 was used as an indicator of developmental regulation to narrow down 
the list. The genes having fold changes above 1.45 were chosen for further research. One 
example is Pou4f2, which has a fold change of 114. There is no difference among E13.5, 
E18.5 and P21 at or below this fold change, for example, see Smad 3 and Med6 (Fig.16). 
 RT-PCR conditions were optimized to ensure that gene expression remained in the 
exponential stage. Optimized conditions also eliminates all non-specific bands. In cases 
where optimizing conditions could not be achieved, new primers were designed and 
used.  
 
2.4 Real time PCR 
   Real time PCR was conducted to quantitatively analyze the expression of the 
short-listed candidate SOXC protein partners. The efficiency of each primer from the 
short-listed candidate SOXC protein partners was tested on 3 biological replicates of 
cDNA generated from murine kidneys at E13.5. Each analysis was conducted in 
triplicate using the Rotor-Gene 3000 detection system (Corbett Research Inc.) with 
PerfeCtaTM SYBR Green FastMixTM, Low ROXTM (Quanta Biosciences Inc.) on 5!l of 
cDNA template using optimized primer concentrations. Each gene was tested on 5 
dilutions including 1X, 10X, 20X, 50X and 100X. The primer concentrations and 
betaine were used to optimize reactions to obtain >0.99 R2 and >0.95 efficiency. The 
Rotor-Gene6 software (Qiagen Inc.) was used to analyze the data and generate a 
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standard curve. 
The primer efficiency must be over 0.95 to obtain a precise comparison. 
Therefore, the accuracy of the series dilution and cDNA template is critical. Vortex and 
pipetting were absolutely precise (Table 3).  
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Table 3. Primer concentrations used to test short-listed potential protein partners of 
SoxC transcription factor; E (primer efficiency), R2 (coefficient of determination in linear 
regression) value and standard curve (CT value over cDNA concentration) on each 
short-listed potential protein partner with standard error. R= Square root of correlation 
coefficient; M= Slope, B=intercept, according to the formula y=mx+b; n=3. 
Gen
e 
Primer 
concent
ration 
Efficienc
y  
R^2 
Standard curve 
Dlx2 200nM R2 =0.99 
E=1.01 
  
 
Pax
7 
200nM R2 =0.99 
E=1.00 
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Dlx5 200nM R2 =0.99 
E=1.05 
 
Pax
6 
200nM R2 =0.99 
E=1.03 
 
Pax
3 
200nM R2 =0.99 
E=0.97 
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Pou
3f2 
200nM R2 =0.99 
E=0.97 
 
Hda
c9  
300nM R2 =0.99 
E=0.97 
 
Cxxc
4 
200nM R2 =1.00 
E=0.98 
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Pou
3f1 
200nM R2 =0.99 
E=0.96 
 
Hhe
x 
300nM R2 =1.00 
E=0.95 
 
Ube
2c 
300nM R2 =1.00 
E=1.00 
 
Pou
4f1 
300nM R2 =1.00 
E=0.98 
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Med
18 
300nM R2 =1.00 
E=1.00 
 
Egr1 300nM R2 =0.99 
E=1.00 
 
Myst
1 
300nM R2 =1.00 
E=1.00 
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Hox
b4 
300nM R2 =1.00 
E=1.01 
 
Ube
2i 
300nM R2 =1.00 
E=1.05 
 
Pou
2f1 
300nM R2 =1.00 
E=1.01 
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Egr3 300nM R2 =1.00 
E=0.98 
 
Sma
d6 
300nM R2 =1.00 
E=1.01 
 
Dlx3 200nM R2 =0.99 
E=0.99 
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Med
27 
300nM R2 =1.00 
E=1.01 
 
Sf1 300nM R2 =1.00 
E=1.00 
 
Dlx1 200nM R2 =1.00 
E=1.00 
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Med
12 
300nM R2 =1.00 
E=0.98 
 
Med
4 
300nM R2 =1.00 
E=0.99 
 
Egr2 200nM R2 =1.00 
E=0.97 
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Hda
c8 
300nM R2 =1.00 
E=0.99 
 
Sma
d3 
300nM R2 =1.00 
E=1 
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For the quantitative comparison, each gene analysis was performed on three 
biological replicates of E12.5, E14.5, E18.5, P7 and P21 murine kidney cDNA in 
triplicate in a single run using optimized conditions. In addition, 
Gapdh, Pgk1 and Hprt1 were evaluated as reference genes using all three biological 
replicates for each time point. Pgk1 was determined to be the most stable reference gene 
using both the NormFinder (Andersen et al., 2004) and BestKeeper (Pfaffl et al., 2004) 
algorithms. Therefore, the Pgk1 was used as the reference gene.  Real-time PCR 
experiments and analyses were conducted following the Minimum Information for 
Publication of Quantitative Real-Time PCR Experiments (MIQE) guidelines (Bustin et 
al., 2010). The threshold of 0.2 was chosen as the default threshold because it was found 
to be optimal to distinguish signal and background fluorescence. 
 
2.5 Analysis 
     Relative quantifications were used to compare the expression level of each gene at 
five time points. The Ct number is the number of PCR amplification cycles required to 
reach fluorescent intensity above threshold. It was measured for each gene and each 
developmental time point was analyzed.  
The gene expression of different time points was normalized against Pgk1 data by 
using $$Ct method (Pfaffl et al., 2004) to detemine the relative expression of each 
shortlisted candidate partners over kidney development, where $$Ct = ((Ct (target) - Ct 
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(PGK1))-(Ct (calibrator gene) - Ct (PGK1)). The Ct value of each gene on P21 was used 
as the calibrator because this value is always the lowest.  
     To evaluate differences in mean relative quantification of each candidate partner 
during renal development, one-way ANOVA followed by Tukey's test was performed, 
using Microsoft® Excel (v1.10, Microsoft Inc). The statistical significance was defined as  
p < 0.05. Graphs were generated using SigmaPlot (v 5.0, SPSS Science Inc). 
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3. RESULTS 
 
3.1 List of potential SOXC protein partners 
 
    A list of candidate protein partner genes was compiled based on the literature and 
was expanded to include members of the same family based on gene sequence and 
phylogenetic homology (Table 4). 
For example, SOX11 was shown to interact with Pou class 3 homeobox 3 (POU3F3) 
and Pou class 3 homeobox 2 (POU3F2) in the activation of the Fibroblast growth factor 
4 enhancer (FGF4) in the hindbrain (Kuhlbrodt et al., 1998a). The Pou family has a 
highly conserved DNA binding structure, and is defined as a family of transcriptional 
regulators (Klemm et al., 1994; Sakurai et al., 2013). Therefore, the POU family proteins 
encoded by Pou genes were assumed to have the potential to interact with SOXC in 
transcription.  
The following families are a few more examples of potential protein partners that 
were identified based on the literature search. 
The Runt-related transcription factor (RUNX) family of proteins are also potential 
SOXC transcription protein partners. The RUNX proteins are poor activators on their 
own, and they tend to interact with transcriptional coactivators (Durst and Hiebert, 2004). 
The RUNX1 gene is thought to be involved in the development of normal hematopoiesis 
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(hemopoiesis). Mouse embryos with homozygous mutations of Runx1 die at about 12.5 
days of gestation (Wang et al., 1996; Fujita et al., 2001; Okuda et al., 2001). 
RUNX2 protein is a key transcription factor associated with osteoblast differentiation 
(Schroeder et al., 2005) and SOX9 can interact with RUNX2 to repress RUNX2 activity 
(Zhou et al., 2006). Runx3 null mice exhibit hyperplasia of the gastric mucosa due to 
stimulated proliferation and suppressed apoptosis in epithelial cells (Li et al., 2002) and 
it has also been reported to cooperate with RUNX2 to regulate the differentiation and 
maturation of chondrocyte (Kim et al., 2013).  
     Early growth response (EGR) is an immediate-early growth response protein 
encoded by the Egr gene. It participates in the transcriptional regulation of genes and is 
induced by mitogenic stimulation. SOX10 protein has been shown to interact with EGR2 
to regulate Connexin32 expression in glial cells (Bondurand et al., 2001).  
  Steroidogenic factor 1 (SF1) is a key component of the pathway of gonadal and 
adrenal development. The SOX9 protein can bind to an SF1 protein partner to regulate 
Amh gene expression in Sertoli cells (de Santa Barbara et al., 1998; Barrionuevo et al., 
2012). 
  Paired box (PAX) is a family of tissue specific transcription factors. It contains a 
paired domain and a partial or complete homeodomain. PAX proteins are noteworthy 
because they are essential for the formation and specification of certain tissues in early 
animal development. SOX10 protein functions during melanocyte specification and in 
the melanocyte lineage, but must interact with PAX3 to regulate 
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microphthamia-associated transcription factor and c-ret gene in neural crest cells in 
order to function successfully (Kuhlbrodt et al., 1998b; Leon et al., 2009). 
   Distal-less homeobox (DLX) is a family of homeobox transcription factors 
similar to the Drosophila distal less gene. DLX5 has been reported to interact with the 
HMG domain of SOX10, but the function of the interaction has not been studied 
(Wissmuller et al., 2006). In the fly, Dlx2 can control development of the branchial 
arches and the forebrain (Qiu et al., 1995). However, whether members of the DLX 
family interact with protein partners, or have a role in murine development is not known. 
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Table 4. Candidate SoxC signaling partners based on literature search. 
 
Interacting Protein Sox 
Family 
Member 
Homologous Genes from 
Same Family 
    CtBP (C-terminal 
binding protein ) 2 
Sox6 
(Murakami et al., 
2001) 
Ctbp1 
DLX (Distal-less 
homeobox) 5 
SOX10 
(Wissmuller et 
al., 2006) 
Dlx1,Dlx2, Dlx3, Dlx4, 
Dlx6 
EGR (Early growth 
response) 2 
SOX10 
(Bondurand et 
al., 2001) 
Egr1, Egr2, Egr3 
EP (E1A binding protein) 300 SOX9 
(Cheng et al., 
2009) 
 
HDAC (histone 
deacetylase) 1 
SOX6 
(Iguchi  et 
al.,2007) 
Hdac1, Hdac2, Hdac4, 
Hdac7, Hdac8, Hdac9, Hdac11 
HHEX 
(hematopoietically expressed 
homeobox) 
SOX13 
(Marfil et al., 
2010) 
 
HnRPK (heterogeneous 
nuclear ribonucleoprotein K) 
SOX10 
(Melnikova et 
al., 2000) 
 
HOX (homeobox) B1 SOX2 
(Wilson et al., 
2002) 
Hoxa2, Hoxa4, Hoxa6, 
Hoxa10, Hoxb1, Hoxb4 
MED (mediator complex 
subunit) 12 
SOX9 
(Akiyama  et 
al., 2011) 
Med1, Med4, Med6, 
Med12, Med15, Med17, 
Med18, Med21, Med23, 
Med25, Med25, Med27, 
Med28, Med29, Med30 
MEF (myocyte enhancer 
factor) 2C 
SOX18 
(Hosking et al., 
2001) 
Mef2a, Med2b, Mef2c, 
Mef2ds 
NHERF2 SRY 
(Thevenet et al., 
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2005) 
OLIG (oligodendrocyte 
lineage transcription factor) 2 
SOX10 (Liu 
et al., 2007) 
Olig1, Olig2, Olig3 
OTX (orthodenticle 
homeobox) 2 
SOX9 
(Masuda  et al., 
2010) 
Otx1, Otx2 
P (tumor protein) 53 SOX4 (Hur 
et al., 2010) 
P53, P63, P73 
PAX (paired box) 3 SOX10 
(Kuhlbrodt et al., 
1998b) 
Pax2, Pax3, Pax4, Pax5, 
Pax6, Pax7, Pax8 
    PGC(Peroxisome 
Proliferator-Activated 
Receptor Gamma, 
Coactivator) 1a 
SOX6 (Liao 
et al., 2010) 
Pgc1b 
POU (pou class) 3f3 SOX11 
(Kuhlbrodt et al., 
1998a) 
Pou1f1, Pou2f1, Pou2f3, 
Pou3f1, Pou3f2, Pou3f3, 
Pou4f1, Pou4f2, Pou4f3, 
Pou5f1 
RUNX (runt-related 
transcription factor) 2 
SOX9 
(Zhou et al. 
2006) 
Runx1, Runx2, Runx3 
SF (splicing factor) 1 SOX9 (de 
Santa Barbara et 
al., 1998) 
 
SMAD1 SOX9 (Kim 
and Lassar, 
2003) 
Smad1, Smad2, Smad3, 
Smad4, Smad5, Smad6, Smad7, 
Smad9 
TIP60 (K(lysine) 
acetyltransferase) 
SOX9 
(Hattori  et al., 
2008) 
Myst2, Myst3, Cbp 
UBE 
(ubiquitin-conjugating 
enzyme) 2I 
SOX4 (Pan 
et al., 2006) 
Ube2a, Ube2b, Ube2c, 
Ube2d1, Ube2d2, Ube2d3, 
Ube2f, Ube2g1, Ube2h, Ube2i, 
Ube2j1, Ube2j2, Ube2k 
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3.2 RT-PCR 
This first step resulted in a short list of 28 SoxC signaling candidate partners 
which are highly developmentally regulated in the murine kidney. These include Pax7, 
Dlx5, Pax4, Pax6, Pou4f3, Pou4f2, Dlx4, Pou3f2, Hdac9, Cxxc4, Pou3f1, Hhex, Ube2c, 
Pou4f1, Med18, Egr3, Smad6, Dlx3, Med27, Sf1, Dlx1, Med12, Med4, Egr2, Hdac8 and 
Smad3 (Table 5). 
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Table 5. Fold change of expression level from E13.5 to P21 of short-listed candidate 
SOXC signaling partners.   
Candidate SOXC signaling 
partner 
Fold change (E13.5/P21) 
Pax7 493 
Dlx5 452.5 
Pax4 293.25 
Pax6 247.25 
Pou4f3 242.75 
Pax3 224 
Pou4f2 113 
Dlx4 85.25 
Pou3f2 50.5 
Hdac9 14.15116 
Cxxc4 4.671576 
Pou3f1 4.231915 
Hhex 3.242424 
Ube2c 3.042424 
Pou4f1 2.938499 
Med18 2.678788 
Egr1 2.674051 
Myst1 2.556465 
Hoxb4 2.429379 
Ube2i,26 1.991266 
Pou2f1 1.920755 
Egr3 1.850987 
Smad6 1.824271 
Dlx3 1.757213 
Med27 1.681951 
Sf1 1.551515 
Dlx1 1.521682 
Med12 1.495323 
Med4 1.492754 
Egr2 1.462827 
Hdac8 1.428571 
Smad3 1.401124 
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3.3 Realtime PCR 
 
      Real time qPCR was used to analyze the mRNA expression patterns of short 
listed candidate protein partners in order to identify those that are developmental 
expressed during renal development and to identify protein partners that have a similar 
mRNA expression pattern as the SoxC subfamily members.  
      Based on a primer efficiency test, Dlx4, Dlx6, Pax4, Pou4f2 and Pou4f3 were 
excluded out of the list of potential SOXC signaling partners because the expression 
levels were too low to have eligible primer efficiencies. Real-time PCR analysis using 
cDNA from murine kidneys at E12.5, E14.5, E18.5, P7 and P21 was performed to study 
the expression pattern of the SOXC candidate partners. From the 28 candidate partners 
analyzed, several genes showed similar expression patterns to the SoxC subfamily.  
       Based on the real-time PCR showing the mRNA expression pattern of each 
short listed potential protein partner of SOXC subfamily, Dlx2, Dlx3 and Dlx5 from the 
Dlx family (Fig. 8), Pou3f1and Pou3f2 from the Pou family (Fig. 9), Pax3, Pax6 and 
Pax7 from the Pax family (Fig. 10), Ube2i and Ube2c from the Ube family (Fig. 11), 
Med4, Med12, Med18 and Med21 from the Med family (Fig. 12), Cxxc4 (Fig. 13) and 
Sf1 (Fig. 14) showed similar mRNA expression patterns as SoxC subfamily members. In 
contrast, the mRNA expression pattern of Egr1, Egr2, Egr3, Smad3, Smad6, Hdac8, 
Hdac9, Hoxb4 and Hhex was dissimilar to that of the SoxC subfamily (Fig. 15).  
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Figure 8. Developmental expression of Dlx1, 2, 3 and 5 in E12.5, E14.5 E18.5, P7 and 
P21 murine kidney measured by real-time PCR. Each data point is calibrated against the 
expression of each gene at P21 using the 2-$$Ct method. Error bars indicate standard error 
(n=3). Differences among the letters above the bars indicate a significant (P < 0.05) 
difference from one-way ANOVA followed by Tukey's test. 
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Figure 9. Developmental expression of Pou class 3 homeobox 2 (Pou3f2) and 1 (Pou3f1), 
Pou class 4 homeobox1(Pou4f1) and Pou class 2 homeobox1(Pou2f1) in E12.5, E14.5 
E18.5, P7 and P21 murine kidney measured by real-time PCR. Each data point is 
calibrated against the expression of each gene at P21 using the 2-$$Ct method. Error bars 
indicate standard error (n=3). Differences among the letters above the bars indicate a 
significant (P < 0.05) difference from one-way ANOVA followed by Tukey's test. 
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Figure 10. Developmental expression of paired box (Pax) 3, 6 and 7 in E12.5, E14.5 
E18.5, P7 and P21 murine kidney measured by real-time PCR. Each data point is 
calibrated against the expression of each gene at P21 using the 2-$$Ct method. Error bars 
indicate standard error (n=3). Differences among the letters above the bars indicate a 
significant (P < 0.05) difference from one-way ANOVA followed by Tukey's test. 
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Figure 11. Developmental expression of Ubiquitin-conjugating enzyme E2C (Ube2c) 
and E2I (Ube2i) in E12.5, E14.5 E18.5, P7 and P21 murine kidney measured by 
real-time PCR. Each data point is calibrated against the expression of each gene at P21 
using the 2-$$Ct method. Error bars indicate standard error (n=3). Differences among the 
letters above the bars indicate a significant (P < 0.05) difference from one-way ANOVA 
followed by Tukey's test. 
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Figure 12. Developmental expression of mediator complex subunit (Med) 4, 12, 18 and 
27 in E12.5, E14.5 E18.5, P7 and P21 murine kidney measured by real-time PCR. Each 
data point is calibrated against the expression of each gene at P21 using the 2-$$Ct 
method. Error bars indicate standard error (n=3). Differences among the letters above 
the bars indicate a significant (P < 0.05) difference from one-way ANOVA followed by 
Tukey's test. 
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Figure 13. Developmental expression of splicing factor 1(Sf1) in E12.5, E14.5 E18.5, P7 
and P21 murine kidney measured by real-time PCR. Each data point is calibrated against 
the expression of each gene at P21 using the 2-$$Ct method. Error bars indicate standard 
error (n=3). Differences among the letters above the bars indicate a significant (P < 0.05) 
difference from one-way ANOVA followed by Tukey's test. 
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Figure 14. Developmental expression of CXXC finger protein 4(Cxxc4) in E12.5, E14.5 
E18.5, P7 and P21 murine kidney measured by real-time PCR. Each data point is 
calibrated against the expression of each gene at P21 using the 2-$$Ct method. Error bars 
indicate standard error (n=3). Differences among the letters above the bars indicate a 
significant (P < 0.05) difference from one-way ANOVA followed by Tukey's test. 
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Figure 15. (A-D) Expression of Smad3,6 (A), Hdac8,9 (B), Egr1,2,3(C) Hoxb4 and 
Hhex (D) in E12.5, E14.5 E18.5, P7 and P21 murine kidney measured by real-time PCR. 
Each data point is calibrated against the expression of each gene at P21 using the 2-$$Ct 
method. Error bars indicate standard error (n=3). Differences among the letters above 
the bars indicate a significant (P < 0.05) difference from one-way ANOVA followed by 
Tukey's test. 
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4. DISCUSSION 
 
4.1 The shortlist of SOXC candidate partners 
 
     mRNAs of all three members of the SoxC subfamily have been found to be 
developmentally regulated in the kidney, with greater expression of SoxC mRNA in the 
early stages of renal development and decreasing expression in later stages (Huang et al., 
2013). SOX protein partners are believed to increase stability of SOX transcription 
factors binding on target genes whether physically bound to Sox transcription factors or 
not (Kondoh and Kamachi, 2010), and it is believed that potential protein partners of 
SOXC transcription factors have similar expression patterns as the transcription factors 
with which they partner. Based on the pixel intensity of all tested candidate SOXC 
partners gel electrophoresis images, 28 candidate partners were short listed for 
quantitative analysis. Collagen type II, alpha 1 (Col2a1) was excluded from the short list, 
because Col2a1 encodes the pro-alpha (II) chain, which is one component of type II 
collagen. Type II collagen provides the structure and strength to connective tissues and 
is mainly found in cartilage (Chan et al., 1995) and Col2a1 is expressed in the renal 
hilum and renal pelvis. It is believed that COL2A1 functions in connective tissue 
formation in the kidney but not nephrogenesis. 
 
!'-!
4.2 Dlx family expression 
    The DLX family of proteins participate in a variety of developmental processes 
in the mouse such as neurogenesis and hematopoiesis (Panganiban et al., 2002). The 
mRNA expression pattern of Dlx2 (Fig. 8) was similar to Sox4 mRNA expression 
(Huang et al., 2013), in that the expression was greatest in the earlier stages of the renal 
development (E12.5) and then decreased with advancing renal development, with the 
exception of a peak at P7 (Fig. 8). Dlx2 and Dlx5 come from the same clade of the 
phylogenetic tree (Stock et al., 1996), and they play similar roles in mouse lens 
development (Kwakowsky et al., 2007), which suggests that they have high 
developmental relevance during lens development. DLX5 has been reported to interact 
at the protein level with SOX10 (Wissmuller et al., 2006). Because of the similarity to 
DLX5, DLX2 may also interact with SOX proteins. For these reasons, both DLX2 and 
DLX5 are considered to have a high potential of being protein partners of SOXC 
transcription factors. 
       Dlx3 mRNA expression pattern was similar to both Sox11 and Sox12 (Huang et 
al., 2013), with greater expression in the early stages of kidney development (Fig. 8). 
Dlx3 is expressed in the nephrogenic zone where SoxC mRNA is expressed at E14.5 in 
the murine kidney (Genepaint, 2003), therefore DLX3 has a high potential of being a 
protein partner of the SOXC transcription factors. Since Dlx1 did not show a similar 
mRNA expression pattern to the SoxC subfamily (Fig. 8), it was excluded as a potential 
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SoxC protein partner.  
 
4.3 Pou family expression 
 
       The Pou domain protein family was derived from three transcription factors; 
PIT-1, OCT-1as well as the nematode protein UNC-86 (Latchman, 1999; Lodato et al., 
2013). The POU family members have various functions, such as those related to 
the neuroendocrine system (Lodato et al., 2013). Based on the real-time PCR data the 
Pou3f1 and Pou3f2 shared similar expression patterns with Sox11 and Sox12 (Huang et 
al., 2013), where there is a significant decreasing expression throughout renal 
development (Fig. 9). The Pou domain of POU3F1 (also called Octamer-binding protein 
7) was reported to be capable of replacing the Pou domain of OCT3/4. The Pou domain 
of OCT 3/4 is essential for its ability to bind to the SOX2 transcription factor to regulate 
UTF (Undifferentiated embryonic cell transcription factor) 1 in pluripotent embryonic 
cells through the Pou domain (Nishimoto et al., 1999). Since OCT3/4 can interact with 
the Sox2 transcription factor, there is a possibility that POU3F1 is a protein partner of 
the SOXC transcription factors. In addition, according to in situ hybridization data, there 
is significant expression of Pou3f1 in the nephrogenic zone in murine kidney at E14.5 
(Genepaint, 2003) where SoxC mRNA is expressed. Therefore, POU3F1 has the 
potential to be a SOXC signaling partner.  
        For POU3F2 (Brain-specific homeobox/POU domain protein 2), there is 
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evidence showing that all three members of the SOXB1 subfamily (SOX1, SOX2 and 
SOX3) can play a role as DNA binding proteins to interact with POU3F2 to regulate the 
Nestin geneural primordial cells (Tanaka et al., 2004). Also, the expression of Pou3f2 is 
reported in NPC in murine kidney at E15.5 (Gray et al., 2004). Because Sox4 and Sox12 
mRNA have been shown to be expressed in NPC and ureteric bud tips during murine 
renal development (Huang et al., 2013), POU3F2 is considered a potential SoxC 
signaling partner. Since Pou4f1 and Pou2f1 did not show similar mRNA expression 
patterns to the SoxC subfamily in the developing kidney (Fig. 9), they were excluded as 
potential SOXC signaling partners.  
 
4.4 Pax family expression 
 
       Pax3 has been reported as being expressed in the stromal cells and nephron 
progenitor cells of the developing kidney (Hueber et al., 2009). It has been shown that 
SOX10 and PAX3 can physically interact to mediate the conserved c-RET enhancer. 
This also supports the notion that PAX3 can be a SOXC signaling partner because 
c-RET, which is expressed in the ureteric bud tips, can cooperate with WNT11 and 
GDNF to regulate ureteric branching during renal development (Majumdar et al., 2003; 
Leon et al., 2012) and Sox4/Sox12 are expressed at ureteric bud tips (Huang et al., 2013). 
Therefore it is possible that the SOXC subfamily interacts with PAX3 in the regulation 
of c-RET. Since the mRNA expression pattern of Pax3 (Fig. 10) is similar to the 
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expression pattern of Sox4 in renal development (Huang et al., 2013), PAX3 is a 
possible signaling partner of SOXC transcription factors.  
     Pax7 and Pax6 mRNAs expression also showed similar patterns (Fig. 10) to Sox11 
and Sox12 in renal development (Huang et al., 2013). PAX6 protein has been reported to 
directly and positively regulate its own gene expression as well as Sox2 expression (Aota 
et al., 2003). Furthermore, SOX3 protein can interact with PAX6 to activate the head 
surface ectoderm-specific enhancer of Pax6 synergistically with PAX6 (Aota et al., 2003; 
Modrell et al., 2011). Also, there is evidence showing that PAX6 can interact with 
SOX10 via its DNA-binding domain in a yeast two-hybrid screen (Wissmuller et al., 
2006). Although there is no prior evidence to support Pax6 and Pax7 expression in renal 
development, there is still a possibility that PAX6 and PAX7 are SOXC signaling 
partners since the online database examined Pax6 and Pax7 expression at one or two 
time points during renal development. The spatiotemporal expression of Pax6 and Pax7 
during mouse kidney development will be identified by in situ hybridization in future 
work.  
  
4.5 Ube family expression 
 
        UBE2I (ubiquitin conjugating enzyme 9) has been identified as a 
SOX4-interacting protein by yeast two-hybrid screen (Pan et al., 2006). Ube2i was also 
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shown to be co-localized with Sox4 in the nucleus of living cells by fluorescence 
microscopy analyses. In addition, the HMG domain, which usually mediates the 
interactions between SOX transcription factors and partner proteins, was found to be 
required for the interaction between SOX4 and UBE2I. UBE2I has also been identified 
as participating in the repression of SOX4 transcriptional activity in a human breast 
cancer cell line (Pan et al., 2006). Although the mechanisms by which UBE2I represses 
the transcriptional activity of SOX4 are still unknown, UBE2I is believed to act as a 
protein partner of SOX4. The expression pattern of Ube2i mRNA (Fig. 11) during 
murine renal development is similar to the expression pattern of Sox4 mRNA (Huang et 
al., 2013). Ube2i mRNA expression has also been detected in the nephrogenic zone of 
the murine kidney at E14.5 by in situ hybridization (Genepaint, 2003). This evidence 
supports the notion that UBE2I may play a repression role as it partners with Sox4 in 
mouse kidney development.  
      There is no current evidence supporting the suggestion that the UBE2C protein 
interacts with other transcription factors. However, the expression pattern of Ube2c 
mRNA (Fig. 11) was similar to the expression pattern of Sox11 and Sox12 mRNA 
(Huang et al, 2013), and there is significant Ube2c expression at the nephrogenic zone 
where the SoxC subfamily is expressed based on in situ hybridization (Genepaint, 2003). 
Though there is no direct evidence of an Ube2c/SoxC interaction reported, I cannot 
exclude the possibility that Ube2c is a protein partner of SoxC signalling. 
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4.6 Med family expression  
 
     The Mediator complex (MED) family interacts with the RNA polymerase II 
enzyme and is considered a transcription cofactor and a global regulator of transcription 
with gene-selective functions (Taatjes, 2010). For example, MED1 is able to activate the 
transcription of thyroid hormone receptor (TR)-regulated promoters (Pandey et al., 2005). 
MED12 (also called thyroid hormone receptor-associated protein, 230 kDa subunit) has 
been reported to interact with SOX9 both in vitro and in vivo and, by 
immunofluorescence, to co-localize with Sox9 in human embryonic chondrocytes (Zhou 
et al., 2006). The C-terminal domain of MED12 can also inhibit SOX9-mediated 
activation, suggesting that an interaction with MED12 is required for the biological 
function of SOX9 (Zhou et al., 2002). MED 12 has also been reported to interact with 
G9A methyltransferase to regulate a subset of neuronal genes (Taatjes, 2010). Med12 
expression is detected in the nephrogenic zone of the murine kidney at E14.5 where 
SoxC expression is detected by in situ hybridization (Genepaint, 2003). With the mRNA 
expression pattern of Med12 (Fig. 12) being similar to the mRNA expression pattern of 
Sox4, it can be concluded that MED12 is a significant candidate SOXC signaling 
partner. 
        Med27 also shares a similar mRNA expression pattern (Fig. 12) as Sox4 
mRNA expression pattern (Huang et al., 2013). Med27 expression was detected in the 
ureteric bud tips of murine kidney at E14.5/E15.5 co-localized with SoxC expression 
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from the in situ hybridization data (Genepaint, 2003; Gray et al., 2004). However, there 
is no evidence reported that MED27 can interact with SOX transcription factors. Since 
Med27 shares a similar mRNA expression pattern as Sox4 expression in both real-time 
PCR and in situ hybridization, MED27 will still be classified as a candidate partner of 
SOXC transcription factors.  
         Med4 and Med18 also share similar mRNA expression patterns (Fig. 12) as 
Sox4 mRNA (Huang et al., 2013). Med4 and Med18 expression is detected in the 
nephrogenic zone of murine kidneys at E14.5 where SoxC is expressed (Genepaint, 
2003). However, there is no evidence reported that MED4 and MED18 can interact with 
SOX transcription factors. Since Med4 and Med18 share a similar mRNA expression 
pattern as Sox4 in both real-time PCR and in situ hybridization, MED4 and MED18 will 
be chosen as candidate partners of SOXC transcription factors.  
 
 
4.7 Expression of other genes 
 
   The mRNA expression pattern of Sf1 (Fig. 13) is similar to that of Sox4 (Huang 
et al., 2013), where the expression was greatest in the earlier stages of the mouse renal 
development (E12.5) and then decreased throughout development with the exception of 
a peak at P7. SF1 was also reported to cooperate with SRY to up-regulate Sox9 e 
expression, and SOX9 also binds to the enhancer of Sf1 to regulate its own expression 
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during murine gonad formation (de Santa Barbara et al., 1998; Barrionuevo et al., 2012). 
Sf1 mRNA expression was also detected in the ureteric bud tips at E15.5 mouse kidney 
where Sox4 and Sox12 were expressed based on the GUD map (Gray et al., 2004) and 
Genepaint (2003). This supports the notion of SF1 being a potential protein partner of 
SOXC transcription factors.  
CXXC4, also called IDAX, has been reported as a DVL binding protein to repress 
the WNT dependent beta-catenin accumulation in mammals (Hino et al., 2001). 
WNT/beta-catenin signaling is critical for nephrogenesis. There is evidence showing that 
two WNT members, WNT4 and WNT9B, can induce the formation of renal vesicles via 
the canonical WNT signaling pathway and that this requires beta-catenin (Park et al., 
2007). The SOX4 transcription factor has been reported to bind to and stabilize 
beta-catenin in canonical WNT signaling (Kormish et al., 2010). From the real-time PCR 
data, the mRNA expression pattern of Cxxc4 (Fig. 14) is similar to the expression pattern 
of Sox11 and Sox12 (Huang et al., 2013). We conclude that there is a possibility that 
CXXC4 is a protein partner of SOXC transcription factors. 
 
4.8 Genes that did not show similar expression pattern to SOXC subfamily 
Expression analysis of Egr1, Egr2, Egr3, Smad3, Smad6, Hdac8, Hdac9, Hoxb4 
and Hhex in embryonic and postnatal renal development (Fig. 15), showed mRNA 
expression patterns that differed when compared to the SoxC subfamily (Huang et al., 
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2013). Since the signaling partners of SOXC transcription factors should share similar 
mRNA expression pattern as the SOXC transcription factor in order to interact, these 
genes were excluded as candidate SOXC signaling partners.  
The limitation of this work is that there is still a possibility that the genes with low 
expression pattern are partners of SOXC transcription factors. However, since the 
accuracy of real time PCR was low in those genes expressed low during murine renal 
development, I have to exclude those genes due to the technical defects. My work is an 
initial study providing fundamental information necessary for further study of 
interaction of SOXC protein partners and SOXC transcription factors.   
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5. CONCLUSIONS 
 
 
5.1 Summary 
 
      Based on my data and the literature search, DLX2, DLX3, DLX5, POU3F1, 
POU3F2, PAX3, PAX6, PAX7, UBE2I, UBE2C, MED4, MED12, MED18, MED21, 
CXXC4 and SF1 all have high potential to be protein partners of SOXC transcription 
factors during nephrogenesis. Their interactions could play a role in the control of 
nephrongenesis during murine renal development. In the near future, co-localization and 
functional interaction between SOXC transcription factors and their protein partners will 
be explored. This will allow for a comprehensive understanding of the SOXC regulatory 
network during kidney development. 
     Overall, my research provides the foundation for an understanding of protein 
partners of SOXC transcription factors and will allow us to comprehensively understand 
the SOXC regulatory network during the kidney development in vivo. It also provides a 
new understanding of the molecular mechanisms of the WT1 signal network during 
nephrogenesis and equips us with a starting point from which to design therapies for de 
novo tissue regeneration based on renal stem cells which could reverse the progression 
of several kidney diseases. 
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5.2 Future Directions 
 
   The current investigation represents the quantitative expression pattern of potential 
SOXC transcription factors protein partners. The next step will focus on localization of 
these protein partners during murine renal development. Indirect immunofluorescence 
double staining or consecutive mRNA in situ hybridization will be performed to 
co-localize potential partners and transcription factors. Since protein partners are 
believed to either bind to SOX transcription factors or bind to the same target gene as 
SOX transcription factors at the close binding sites (Kamachi et al., 2000), protein 
partners and SOXC transcription factors are believed to be expressed in the same 
structures during murine renal development. This will allow us to narrow down the list 
of potential SOXC transcription factors protein partners. Since conditional ablation of 
SOX4 function in the NPC (Sox4 NPC-/-) will cause defects of murine glomeruli 
formation (Huang et al., 2013), analyses of compound SoxC- and potential partners- 
conditional ablation of function in the NPC can be used to identify the functional 
interaction between SOXC transcription factors and potential partners. Also, yeast 
two-hybrid screen can be used to show the physical interaction of SOXC transcription 
factors and their protein partners. Chromatin immunoprecipitation assay or DNA pull 
down assay can be used to identify SOX/Protein partners/target genes interaction.   
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7. APPENDICES 
7.1 APPENDIX A- RNA isolation protocol 
 
Note: 
1. All glassware used during RNA isolation was autoclaved and baked at 2500C to 
ensure that it was RNase/ DNase free. 
2. All required equipment that was not baked such as pipette tips, micro-centrifuge 
tube, collection tube and syringes were sterile. 
3. Surface area where the isolation procedure was carried out was first cleaned with 
70% ethanol, then with RNA Zap to ensure the surface was clean and free of 
RNase/DNase. 
4. Samples being used during the RNA isolation were kept cold on ice to ensure no 
degradation of RNA occurred during the process. 
 
Clean the homogenizer 
  
1. Separate the homogenizer, spray with RNA Zap, wait 5-10 minutes. 
2. Clean homogenizer with 70% ethanol prepared with UltraPure distilled 
(RNase/DNase free) water and then with autoclaved ddH2O between different 
aged samples. 
 
Homogenization of Samples  
 
Note: 
Transfer the needed kidneys to a culture tube containing 350 µl buffer RA1 and 3.5 µl 
beta-mercaptoethanol and put the tube on ice. 
 
Technique 
 
1. Place the culture tube in a beaker containing ice water to keep the tube cold. 
2. Homogenize until no obvious tissue exists. 
3. Transfer the amount of cells to the 0.9 mm needle (20 – 23.5 gauge). 
!(&!
4. Transfer to the RNA spin Mini Filter units in the collection tube.    
 
RNA isolation 
 
Technique 
 
1. Centrifuge the RNA spin Mini Filter units with the collection tube for 1 min at 
14,000 rpm, 40C in the microcentrifuge  
2. Discard the RNA spin Mini Filter. Transfer filtrate to a new 1.5 ml 
microcentrifuge tube.  
3. Add 350 µl 70% ethanol to the homogenized lysate and mix by vortexing. 2 x 5 
sec. 
4. Add 350 µl 70% ethanol again to the homogenized lysate and mix by vortexing. 
2 x 5 sec. 
5. Transfer half of the lysate to the RNAspin Mini column placed in a 2 ml 
microcentrifuge tube. Pipette lystate up and down 2-3 times. Centrifuge for 30 s 
at 11,000 rpm, 40C. Discard the flow through, and return the column to the 
collection tube. 
6. Transfer the rest of the lysate to the RNAspin Mini column placed in a 2 ml 
microcentrifuge tube (Be sure to load all of the precipitate onto the column). 
Pipette lysate up and down 2-3 times. Centrifuge for 30 sec at 11,000 rpm, 40C. 
Pace the column in a new collection tube. 
7. Add 350 µl MDB and centrifuge at 14,000rpm for 1 min, 40C. Discard the 
flow-through and return the column to the collection tube. 
8. Add 10 µl reconstituted DNase I to 90 µl DNase reaction buffer. Mix by flicking 
the tube. Apply 95 µl of DNase reaction mixture directly onto the center of the 
silica membrane of the column. Incubate at room temperature for 15 min. 
9. Add 200 µl buffer RA2 to the RNAspin Mini column. Centrifuge for 1 min at 
14,000 rpm, 40C.Place the column into a new collection tube. 
10. Add 600 µl buffer RA3 to the RNAspin Mini column. Centrifuge for 1 min at 
14,000 rpm, 40C. Discard flow-through and place the column back. 
11. Add 250 µl buffer RA3 to the RNAspin Mini column. Centrifuge for 2 min at 
14,000 rpm,40C. Place the column into a nuclease-free 1.5 ml microcentrifuge 
tube. 
12. Elute the RNA in 100 µl RNase free H20 and set for 2 mins. Centrifuge for 1 min 
at 14,000 rpm,40C. 
13. Elute the RNA again in 100 µl RNase free H20 and set for 2 mins. Centrifuge for 
1 min at 14,000 rpm,40C. 
14. Transfer the microcentrifuge tube with the sample to the -800C. 
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7.2 APPENDIX B- cDNA synthesis protocol 
 
 
    cDNA synthesis is carried out using the qScripttm cDNA synthesis kit. The kit uses 
20 µl synthesis volume and 1 µl of sample. The 1 µg sample is determined by dividing 
1000 ng by the ng/µl reading from Nanodrop 1000. 
 
Components: 
1. 5X Reaction Mix        4µl 
2. Reverse Transcriptase    1µl 
3. Nuclease free water     15-X 
4. mRNA                X   X=1000 ng/Concentration per µl of RNA sample  
 
Example: The concentration of E13.5 kidney RNA determined by Nanodrop is 
285 ng/µl. Therefore, the amount of RNA added to cDNA synthesis will be 1000 
ng/ (285 ng/µl) = 3.5 µl of RNA solution.  
              
For the negative control (Minus-RT Control: Without the Reverse Transcriptase in the 
reaction in order to make sure there is no genomic DNA contamination): 
 
1.  5X Reaction Mix        4 µl 
2.  Nuclease free water     16-X 
 
3.   mRNA:           X   X=1000 ng/Concentration per µl of RNA 
sample  
 
Technique 
 
1. Combine the reagents in a 0.2 ml thin walled PCR tube or micro-centrifuge tube 
and placed over ice. Reverse transcriptase is added in the beginning to ensure it 
has been added and not lost in the preparation.    
2. Vortex gently and then centrifuge for 10 seconds to collect content to the bottom 
of the tube. 
3. Place the tube in the thermal cycler which is programmed as follow:  
1. Forever: 25°C 
2. 1 Cycle: 25°C, 5 minutes 
3. 1 Cycle: 42°C, 30 minutes 
!()!
4. 1 Cycle: 85°C, 5 minutes 
5. Forever: 4°C 
6. Initiate run 
7. After cDNA synthesis, the cDNA was diluted 20X and stored at -20°C.   
 
Notes: All the components prior to and after cDNA synthesis should be kept on ice to 
maintain integrity of the sample and prevent any degradation. 
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7.3 APPENDIX C- List of primer information and sequences for the potential 
SOXC signaling partners 
 
Table 6. List of primer information and sequences for the potential SoxC signalling 
partners. Primer pairs were designed to ensure that primers cross at least one intron 
sequence to reduce risk of co-amplified genomic DNA. Primer pairs that did not cross 
intron-exon boundaries included a negative (-RT) control.  
Name Sequences Accession Nos. Amplicon 
Size 
Intron-exon 
boundary 
Cbp forward AGGTGTTTCAC
AGGGTCAGG 
NM_001025432 113 Yes 
Cbp reverse GGTGCAATGGT
GACTGTGTC 
   
Ctbp1 (p1) 
forward 
GTGCCCTGATG
TACCATACCA 
NM_013502 108 No 
Ctbp1 (p1) 
reverse 
CGGGTTTGACA
ATATCGACATC
A 
   
Ctbp2 forward GGCAGCGATTG
GACAGGATTT 
NM_ 001170744 121 Yes 
Ctbp2 reverse AGGATGGGCAT
CTCCACAGT 
   
Cxxc4 forward ACAGACAGTG
CGTTTCAAATT
GC 
NM_ 001004367 161 NO 
Cxxc4 reverse CCACAGTTGAT
GAGCCTCTTG 
   
Cxxc5 forward CAGGAGGAAC
AGACAAAAGT
ACC 
NM_133687 126 NO 
Cxxc5 reverse GGCTCTTGTTG
AGGGGTTCAC 
   
Dlx1 forward ATGCCAGAAAG
TCTCAACAGC 
NM_010053 118 NO 
Dlx1 reverse AACAGTGCATG
GAGTAGTGCC 
   
Dlx2 forward GGCTCCTACCA
GTACCACG 
NM_004405 133 NO 
Dlx2 reverse CGTTGTTGACC    
!(.!
GGAGACGAA 
Dlx3 forward CACTGACCTGG
GCTATTACAGC 
NM_010055 103 NO 
Dlx3 reverse GAGATTGAACT
GGTGGTGGTAG 
   
Dlx4 forward GCAAGCCCAG
AACCATCTACT 
NM_007867 117 NO 
Dlx4 reverse TGAGTCCGAGT
TGTGCTGC 
   
Dlx5 forward GTCCCAAGCAT
CCGATCCG 
NM_010056 79 NO 
Dlx5 reverse GCGATTCCTGA
GACGGGTG 
   
Dlx6 forward AAAACGACAG
TGATCGAAAAC
GG 
NM_010057 123 NO 
Dlx6 reverse AGTCTGCTGAA
AGCGATGGTT 
   
Egr1 forward CCACAACAAC
AGGGAGACCT 
NM_007913 124 NO 
Egr1 reverse ACTGAGTGGCG
AAGGCTTTA 
   
Egr2(old) 
forward 
GCCAAGGCCGT
AGACAAAATC 
NM_010118 154 NO 
Egr2 
(old)reverse 
CCACTCCGTTC
ATCTGGTCA 
   
Egr3forward CCGGTGACCAT
GAGCAGTTT 
NM_018781 122 NO 
Egr3 reverse TAATGGGCTAC
CGAGTCGCT 
   
Ep300 forward TAAACATGGCT
CCACAACCA 
NM_177821 106 NO 
Ep300 reverse GACCTGAGAGT
CCGCAAAAG 
   
Hdac1  forward AGTCTGTTACT
ACTACGACGGG 
NM_ 008228  101 NO 
Hdac1 reverse TGAGCAGCAAA
TTGTGAGTCAT 
   
Hdac10 forward GTGCGAAATTG
AGTGCCCAG 
NM_199198 102 YES 
Hdac10 reverse GATGCCTCACA    
!((!
AGCTGACAAA 
Hdac11  
forward 
ATCTACCCTGG
GGATCGCTTT 
NM_144919  110 YES 
Hdac11 reverse CTCCTGACATT
CCTCTCCACC 
   
Hdac2(p1)  
forward 
GGAGGAGGCT
ACACAATCCG 
NM_008229  173 YES 
Hdac2(p1) 
reverse 
TCTGGAGTGTT
CTGGTTTGTCA 
   
Hdac3(p2)  
forward 
GGTTCAGGAA
GCCTTCTACCT 
NM_010411    112 YES 
Hdac3(p2) 
reverse 
ACTCTCTGCTC
CAACTTCATAC
A 
   
Hdac5  forward AGCACCGAGGT
AAAGCTGAG 
NM_001077696   91 NO 
Hdac5 reverse GCTGTGGGAG
GGAATGGTT 
   
Hdac6  forward TCCACCGGCCA
AGATTCTTC 
NM_001130416  109 YES 
Hdac6 reverse CAGCACACTTC
TTTCCACCAC 
   
Hdac7  forward TTCCCTTGCGT
AAAACAGTGT 
NM_019572  87 NO 
Hdac7 reverse GCAGGGGATTC
TTGCGTCT 
   
Hdac8  forward ACTATTGCCGG
AGATCCAATGT 
NM_027382 107 NO 
Hdac8 reverse CCTCCTAAAAT
CAGAGTTGCCA
G 
   
Hdac9  forward GCGGTCCAGGT
TAAAACAGAA 
NM_024124   108 NO 
Hdac9 reverse GCCACCTCAAA
CACTCGCTT 
   
Hhex  forward CGGACGGTGA
ACGACTACAC 
NM_008245  150 YES 
Hhex  reverse CTTCTCCAGCT
CGACGGTC 
   
Hnrnpk forward CAGCTCCCGCT
CGAATCTG  
NM_025279   210  Yes  
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Hnrnpk reverse TCTGTCAGTAG
AGTGAGGGCA  
   
Hoxa10 forward CACCACCCACT
CTGGTTTG 
NM_008263 161 YES 
Hoxa10 reverse TGCATTTTCGC
CTTTGGAACT 
   
Hoxa2 forward TACGAATTTGA
GCGAGAGATTG
G 
NM_010451 116 NO 
Hoxa2 reverse GTCGAGGTCTT
GATTGATGAAC
T 
   
Hoxa4 forward GAAAGCACAA
ACTCACAGCCC 
NM_008265 169 NO 
Hoxa4 reverse TGTCTCGGGTT
TACTTAGGGAA
G 
   
Hoxa6 forward CGGCCAGGACT
CCTTCTTG 
NM_010454 143 NO 
Hoxa6 reverse CCGAGTTGGAC
TGTTGGTAAAA 
   
Hoxb4 forward CGTGAGCACG
GTAAACCCC 
NM_010459 231 NO 
Hoxb4 reverse GTGTTGGGCAA
CTTGTGGTC 
   
Hoxd4 forward AAGTACGTGGA
CCCCAAGTTT 
NM_010469 245 NO 
Hoxd4 reverse GGGGCACCGTA
ATGACTTCC 
   
Maf1forward ATTGCCACCCT
CAATGAGTC 
NM_001164607 107 YES 
Maf1 reverse TTGACTGCATT
TACCACCCA 
   
Med1 forward GGCACCCCTGT
TCGAGATTC 
NM_001080118  262 NO 
Med1 reverse CCCCACTCTGA
CTACTTTCATC
A 
   
Med12 forward CAGAGTGCTAT
TAACACCTGGT
T 
NM_177855   179 YES 
!%-%!
Med12 reverse GCTGCATAGTA
GGCACAAGTCA
T 
   
Med15 forward CGCCGGTTTGA
GGAGGATG 
NM_ 033609  128 NO 
Med15 reverse AGGTGGACAGT
ACCGTTGTTG 
   
Med17 forward ATGGCACCGAG
ACGTACCT 
NM_144933 237 YES 
Med17 reverse GGGCACTTCGC
AAATTGTTCC 
   
Med18 forward CACTGGGGGC
ACCATTAACAT 
NM_026039 180 YES 
Med18 reverse CTTAGGACGAA
CGGGCTGG 
   
Med21 forward GCTGTGAACTC
GCTTGCAGA 
NM_025315 122 YES 
Med21 reverse GTAGGATTGGC
TGGTTGATCTT
T 
   
Med23 forward TTAAAGGGCGA
GACCATCTGA 
NM_001166416 73 NO 
Med23 reverse GCGAGGGCATT
TTTCTGAATAC
T 
   
Med25 forward GTGGTGTTTGT
GATCGAGGGG 
NM_029365  215 YES 
Med25 reverse CTGGTAGGTGC
GTGACATTGT 
   
Med27 forward GATCGCACGAT
TGTGAAGGG 
NM_026896 150 YES 
Med27 reverse TGGCATCTGGG
GTAACTGATAG 
   
Med28 forward GCCCCGAGACC
ATCTAACAG 
NM_025895   210 YES 
Med28 reverse CTGGACAGATA
ACTGCAACCTT 
   
Med29 forward GCAGCAGCAG
GACTTCGAT 
NM_026042    195 YES 
Med29 reverse TCACAGAGTGC
GTAAAACTCC 
   
!%-*!
Med30 forward GCTGGTCCACC
TCGTTTTG 
NM_027212 124 YES 
Med30 reverse TGTCCCAGATG
AGATTCCGTAA 
   
Med4  forward CTCGGAGGCCA
TACCCAAC 
NM_026119  130 NO 
Med4 reverse ACATCTGGCAG
TCTACCTGCT 
   
Med6 forward TCTCCTGGGTT
GACAGCTCTT 
NM_27213 112 NO 
Med6 reverse ACCACCTCATT
ATTACACGTCC
T 
   
Mef-2a forward CAGGTGGTGGC
AGTCTTGG 
NM_013597 132 YES 
Mef-2a reverse TGCTTATCCTTT
GGGCATTCAA 
   
Mef-2b forward AGGCTCCACAG
ATTGCAGC 
NM_001045484   82 YES 
Mef-2b reverse TACAGCGTCCC
TCGTTGGT 
   
Mef-2c forward TGCTGGTCTCA
CCTGGTAAC 
NM_025282 148 YES 
Mef-2c reverse ATCCTTTGATT
CACTGATGGCA
T 
   
Mef-2d forward CGAGATCGCGC
TCATCATCTT 
NM_133665 164 YES 
Mef-2d reverse AGCCGTTGAAA
CCCTTCTTCC 
   
Myst1 forward ACGAGGCGATC
ACCAAAGTG 
NM_026370 166 NO 
Myst1 reverse AAGCGGTAGCT
CTTCTCGAAC 
   
Myst2 forward ATGCCGCGAAG
GAAGAGAAAT 
NM_001195004 164 NO 
Myst2 reverse TCTTGGGAACT
CTGGCTTAGC 
   
Myst3  forward CCTCGTGCATT
GGCTGTTC 
NM_001081149 106 NO 
Myst3 reverse TCATGGCATTC    
!%-,!
AAGGTGTTCAT 
Myst4 (p2)  
forward 
TGAGGAAAGC
ATTCCCACATC 
NM_017479  178 YES 
Myst4 (p2) 
reverse 
ACACTTGTCTG
CACTTTAGAGG 
   
Nherf-2 forward CACCTGCATGG
CGAGAAAG  
NM_001130012 128  No  
Nherf-2 reverse TCTACGTTGAC
GCCGTTGAC  
   
Olig1 forward TCTTCCACCGC
ATCCCTTCT 
NM_016968 226 NO 
Olig1 reverse CCGAGTAGGGT
AGGATAACTTC
G 
   
Olig2(p3) 
forward 
GGCGGTGGCTT
CAAGTCAT 
NM_016967 99 NO 
Olig2(p3) reverse GGGCTCAGTCA
TCTGCTTCT 
   
Olig3 forward CAGGAGAGTC
GTCTGAACTCG 
NM_053008 181 NO 
Olig3 reverse GTTCGCGTCCG
TTGATCTT 
   
Otx1 forward ACTGACCCTTC
GCCAGTCTA 
NM_011023 124 NO 
Otx1 reverse AACATTGGACC
TGGAACTCG 
   
Otx2 forward CAGAGGTGATC
CGGTGTTTT 
NM_144841 
 
89 NO 
Otx2 reverse CCTGTTGGTCA
TGAAACGTG 
   
P53 forward CTCTCCCCCGC
AAAAGAAAAA  
NM_001130012 84  Yes  
P53 reverse CGGAACATCTC
GAAGCGTTTA  
   
P63(trp63) 
forward  
CCCAAGTGGTG
CCTCTACC  
NM_011641 113  No  
P63(trp63) 
reverse 
CGTCACGGGGT
GGAAAAGA  
   
P73 forward GCACCTACTTT
GACCTCCCC  
NM_001126330 121  Yes  
P73 reverse GCACTGCTGAG    
!%-&!
CAAATTGAAC  
Pax2(p1) 
forward 
AAGCCCGGAG
TGATTGGTG 
NM_011037 101 NO 
Pax2(p1) reverse CAGGCGAACAT
AGTCGGGTT 
   
Pax3 forward GGGCAGAATTA
CCCACGCA 
NM_008781 177 YES 
Pax3 reverse CTGGCGAGAAA
TGACGCAA 
   
Pax4 forward GACTCAACTCA
GATCACCAGC 
NM_001159926 119 YES 
Pax4 reverse GGGAGAAGATA
GTCCGATTCCT 
   
Pax5 forward CCATCAGGACA
GGACATGGAG 
NM_008782 101 NO 
Pax5 reverse GGCAAGTTCCA
CTATCCTTTGG 
   
Pax6 forward AGGGCAATCGG
AGGGAGTAA 
NM_001244201 186 YES 
Pax6 reverse CAGGTTGCGAA
GAACTCTGTTT 
   
Pax7 forward TCTCCAAGATT
CTGTGCCGAT 
NM_011039 132 YES 
Pax7 reverse CGGGGTTCTCT
CTCTTATACTCC 
   
Pax8(p1) 
forward 
ATGCCTCACAA
CTCGATCAGA 
NM_011040 104 YES 
Pax8(p1) reverse ACAATGCGTTG
ACGTACAACTT 
   
Pgc1a forward AATGCAGCGGT
CTTAGCACT 
NM_008904 121 YES 
Pgc1a reverse TGTTGACAAAT
GCTCTTCGC 
   
Pgc1b forward CCGAGCTCTTC
CAGATTGAC 
NM_133249  116 YES 
Pgc1b reverse TTCATCCAGTT
CTGGGAAGG 
   
Pou1f1(pit1) 
forward 
ATGAGTTGCCA
ATCTTTCACCT
C  
NM_008849 143  No  
Pou1f1(pit1) GCTGTGGACAT    
!%-+!
reverse CACGTTGGT  
Pou2f1(oct1)  
forward 
CCCAACTCGCA
CAATAGCAG 
NM_198933 
 
69 NO 
Pou2f1(oct1) 
reverse 
ATTCGCTTTGG
TGTTGACTGG 
   
Pou2f2 
(new)forward 
CTCGCACCTTC
AAGCAACG 
NM_011138 115 YES 
Pou2f2  
(new)reverse 
TCGAAGCGGG
AAATGGTCG 
   
Pou2f3(oct11)  
forward 
CAGAGACGCAT
TAAGCTAGGC 
NM_011139 120 YES 
Pou2f3(oct11) 
reverse 
GCGAGATGGTA
GTCTGGCT 
   
Pou3f1(oct6) 
forward 
TCGAGGTGGGT
GTCAAAGG 
NM_011141 205 NO 
Pou3f1(oct6) 
reverse 
GGCGCATAAAC
GTCGTCCA 
   
Pou3f2(brn2) 
forward 
CGGATCAAACT
CGGATTTACTC
A 
NM_008899 240 NO 
Pou3f2(brn2) 
reverse 
GGAGGTCCGCT
TTTTCCGT 
   
Pou3f3(brn1) 
forward 
AGCAGTTCGCT
AAGCAGTTCA 
NM_008900 123 NO 
Pou3f3(brn1) 
reverse 
CGAAGCGGCA
GATAGTGGTC 
   
Pou3f4(brn4) 
forward 
CTGCCTCGAAT
CCCTACAGC 
NM_008901 122 NO 
Pou3f4(brn4) 
reverse 
CTGCAAGTAGT
CACTTTGGAGA
A 
   
Pou4f1(brn3a) 
forward  
CGCGCAGCGTG
AGAAAATG  
NM_011143 123  No  
Pou4f1(brn3a) 
reverse 
CGGGGTTGTAC
GGCAAAATAG  
   
Pou4f2(brn3b) 
forward 
TGGACATCGTC
TCCCAGAGTA  
NM_138944 91  No  
Pou4f2(brn3b) 
reverse 
GTGTTCATGGT
GTGGTAAGTGG  
   
Pou4f3(brn3c) 
forward 
CGACGCCACCT
ACCATACC 
NM_138945 114  No 
!%-)!
Pou4f3(brn3c) 
reverse 
CCCTGATGTAC
CGCGTGAT 
   
Pou5f1(oct3,4) 
forward 
AGTTGGCGTGG
AGACTTTGC 
NM_013633 160 No 
Pou5f1(oct3,4) 
reverse 
CAGGGCTTTCA
TGTCCTGG 
   
Runx1 forward GCAGGCAACG
ATGAAAACTAC
T 
NM_009821 161 YES 
Runx1 reverse GCAACTTGTGG
CGGATTTGTA 
   
Runx2 forward ATGCTTCATTC
GCCTCACAAA 
NM_001145920 146 NO 
Runx2 reverse GCACTCACTGA
CTCGGTTGG 
   
Runx3 forward CAGGTTCAACG
ACCTTCGATT 
NM_019732 103 YES 
Runx3 reverse  GTGGTAGGTAG
CCACTTGGG 
   
Sf1 forward ACCTGTAGCAT
CGAGTGTCTT 
NM_011750 151 NO 
Sf1 reverse CTGGAAGGGTC
ACCAATGGG 
   
Smad1 forward TCAATCCTTTT
GTGTGGGGT 
NM_008539 94 NO 
Smad1 reverse GATGATTCAAC
GTGGGCTCT 
   
Smad2 forward TCCCATTCCTG
TTCTGGTTC 
NM_010754 115 NO 
Smad2 reverse ACTGCCCACAC
AAACCTTTC 
   
Smad3 forward GCCTTTGTCTT
CAGCACTCC 
NM_016769 116 NO 
Smad3 reverse AGGCCAGCAC
AGGACTCTAA 
   
Smad4 forward GAGGAGATCGC
TTTTGCTTG 
NM_008540 112 YES 
Smad4 reverse CCAAACGTCAC
CTTCACCTT 
   
Smad5 forward TGCCTTTATGG
GGAGTGAAG 
NM_001164041 93 NO 
!%-'!
Smad5 reverse CCACCCAAGTC
CACAGAACT 
   
Smad6 forward ACAAGCCACTG
GATCTGTCC 
NM_008542 103 YES 
Smad6 reverse GACATGCTGGC
ATCTGAGAA 
   
Smad7 forward CGAGGAGGTG
GTGTGTTTTT 
NM_001042660 120 NO 
Smad7 reverse GAAGACTTGA
GGGAGGGGAC 
   
Smad9 forward AATGAATTTTC
CCCCTTTGG 
NM_019483 114 NO 
Smad9 reverse  TTTGCTTGTCA
GCTTCATGG 
   
Tip60(kat5) 
forward 
TCCCGGTCCAG
ATCACACTC  
NM_001126330 130  Yes  
Tip60(kat5) 
reverse 
ACCTTCCGTTT
CGTTGAGCG  
   
Ube2a forward ATCCTAACGTC
TATGCAGATGG
T  
NM_019668 187  Yes  
Ube2a reverse CGCTTTTCATAT
TCCCGCTTGTT  
   
Ube2b forward GAACCGAATCC
AAACAGTCCA  
NM_009458 100  Yes  
Ube2b reverse TTTGCTCAACA
ATGGCCGAAA  
   
Ube2c forward CTCCGCCTTCC
CTGAGTCA  
NM_026785 132  Yes  
Ube2c reverse GGTGCGTTGTA
AGGGTAGCC  
   
Ube2d1 forward CCCGTGGGAGA
TGACTTGTTC  
NM_145420 110  Yes  
Ube2d1 reverse GGATAGTCTGT
CGGAAAGTGG
A  
   
Ube2d2 forward ACAAGGAATTG
AATGACCTGGC  
NM_019912 123  Yes  
Ube2d2 reverse CACCCTGATAG
GGGCTGTC  
   
Ube2d3 forward AACTTAGTGAT NM_025356 106  Yes  
!%-.!
TTGGCCCGTG  
Ube2d3 reverse GGGCTGTCATT
AGGTCCCATAA  
   
Ube2f forward CCAGATGAGGG
TTACTACCAGG  
NM_026454 110  Yes  
Ube2f reverse GGGTGCCAGAT
TTTAGTCAAGC  
   
Ube2g1 forward CTGGCAGAACT
CAACAAAAATC
C  
NM_025985 137  Yes  
Ube2g1 reverse AGATGAGCCTT
AAAAACACCA
CC  
   
Ube2h forward GACACGGACGT
AGTCAAGCTC  
NM_001169577 135  Yes  
Ube2h reverse GTCCACTCTCA
CTTTCCACAC  
   
Ube2i forward GGAGGAAGGA
CCACCCTTTTG  
NM_001177609 90  Yes  
Ube2i reverse GGATAGCGCAC
TCCCAGTT  
   
Ube2j1 forward ATGGAGACCCG
CTACAACCT  
NM_019586 100  Yes  
Ube2j1 reverse GAGGCTGAGC
GTGGTAATGAT  
   
Ube2j2 forward CAGAGCCCCTC
CCTTCAAATA  
NM_021402 179  Yes  
Ube2j2 reverse CAGCCTTGTGT
TGCACTTAAAT
C  
   
Ube2k forward CAGCGAATCAA
GCGGGAGTT  
NM_016786 125  Yes  
Ube2k reverse AGGTCCTGCTA
TTTCTCCTCTT  
   
Ybx1 forward CAGACCGTAAC
CATTATAGACG
C 
NM_011732 102 NO 
Ybx 1 reverse ATCCCTCGTTC
TTTTCCCCAC 
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7.4 APPENDIX D- RT-PCR conditions 
 
Table 7. RT-PCR condition for all candidate partners:  amount of primer used, 
denaturing temperature, annealing temperature, extension temperature, cycle number 
and betaine if required 
 
Name 
 
Primer  
(µl) 
 
Denaturing 
Temp. (oC)   
 
 
Annealing 
Temp. (oC) 
 
 
 
Extension 
Temp. (oC) 
 
 
 
Cycle 
Number 
 
Addin
g 
Betain
e  
Col2a1  2.5 95 60 45 28 YES 
Cbp  2.5 95 60 45 30 No 
Ctbp1  2.5 95 60 45 45 No 
Ctbp2   2.5 95 60 45 30 No 
Cxxc4   2.5 95 55 45 38 No 
Cxxc5   2.5 95 55 45 45 No 
Dlx1   2.5 95 55 45 38 No 
Dlx2   2.5 95 55 45 38 YES 
Dlx3   2.5 95 55 45 38 No 
Dlx4   2.5 95 55 45 38 No 
Dlx5   1.5 95 65 45 38 No 
Dlx6   2.5 95 55 45 45 No 
Egr1   2.5 95 55 45 30 YES 
Egr2   1.5 95 65 45 38 No 
Egr3  2.5 95 60 45 38 YES 
Ep300   2.5 95 55 45 30 No 
Hdac1   2.5 95 55 45 30 No 
Hdac1
0   
2.5 95 55 45 30 No 
Hdac11   2.5 95 55 45 45 No 
Hdac2   2.5 95 55 45 30 No 
Hdac3   2.5 95 55 45 30 No 
Hdac5   2.5 95 55 45 30 No 
Hdac6   2.5 95 55 45 30 No 
Hdac7   2.5 95 55 45 30 No 
Hdac8   2.5 95 55 45 30 No 
Hdac9   2.5 95 55 45 30 No 
Hhex    2.5 95 55 45 30 YES 
!%%-!
Hnrnp
k  
2.5 95 55 45 30 No 
Hoxa1
0   
2.5 95 55 45 45 No 
Hoxa2   2.5 95 55 45 45 No 
Hoxa4   1.5 95 65 45 38 No 
Hoxa6   2.5 95 55 45 38 No 
Hoxb4   2.5 95 55 45 30 No 
Hoxd4   2.5 95 55 45 38 No 
Maf1  2.5 95 55 45 30 No 
Med1    2.5 95 55 45 30 No 
Med12   2.5 95 60 45 30 No 
Med15   2.5 95 55 45 30 No 
Med17   2.5 95 55 45 30 No 
Med18   2.5 95 55 45 30 No 
Med21   2.5 95 55 45 30 No 
Med23   2.5 95 55 45 30 No 
Med25   2.5 95 60 45 30 No 
Med27   2.5 95 55 45 30 No 
Med28   2.5 95 55 45 30 No 
Med29   2.5 95 55 45 30 No 
Med30   2.5 95 55 45 38 No 
Med4    2.5 95 55 45 30 No 
Med6    2.5 95 55 45 30 No 
Mef-2a   2.5 95 55 45 30 YES 
Mef-2b   2.5 95 55 45 45 YES 
Mef-2c   2.5 95 55 45 45 No 
Mef-2d   2.5 95 55 45 30 No 
Myst1    2.5 95 55 45 30 YES 
Myst2    2.5 95 55 45 30 NO 
Myst3    2.5 95 55 45 30 NO 
Myst4   2.5 95 60 45 30 NO 
Nherf-
2   
2.5 95 55 45 45 NO 
Olig1    2.5 95 55 45 38 NO 
Olig2  2.5 95 60 45 38 YES 
Olig3    2.5 95 55 45 45 YES 
Otx1   2.5 95 55 45 45 YES 
Otx2   1.5 95 60 45 45 YES 
P53   2.5 95 55 45 30 NO 
P63    1.5 95 65 45 38 NO 
!%%%!
P73   1.5 95 65 45 38 NO 
Pax2 2.5 95 55 45 30 NO 
Pax3   2.5 95 55 45 38 NO 
Pax4   2.5 95 60 45 38 YES 
Pax5    2.5 95 55 45 45 YES 
Pax6   2.5 95 55 45 45 NO 
Pax7   2.5 95 55 45 38 NO 
Pax8  2.5 95 55 45 30 NO 
Pgc1a   2.5 95 55 45 30 NO 
Pgc1b   2.5 95 60 45 38 NO 
Pou 
1f1   
2.5 95 55 45 38 NO 
Pou2F
1    
2.5 95 55 45 30 NO 
Pou2F
2   
2.5 95 60 45 38 YES 
Pou2f3  1.5 95 55 45 40 YES 
Pou3f1   2.5 95 55 45 38 NO 
Pou3F
2   
1.5 95 55 45 40 YES 
Pou3F
3 
2.5 95 55 45 30 NO 
Pou3f4  2.5 95 55 45 45 YES 
Pou4f1   2.5 95 55 45 38 NO 
Pou4f2   2.5 95 60 45 45 YES 
Pou4f3   2.5 95 60 45 45 YES 
Pou5f1   1.5 95 55 45 45 YES 
Runx1   2.5 95 55 45 45 NO 
Runx2   2.5 95 55 45 45 NO 
Runx3   2.5 95 55 45 45 NO 
Sf1   2.5 95 55 45 30 NO 
Smad1   2.5 95 55 45 30 NO 
Smad2   2.5 95 55 45 30 NO 
Smad3   2.5 95 55 45 30 NO 
Smad4   2.5 95 55 45 30 NO 
Smad5   2.5 95 60 45 38 NO 
Smad6   2.5 95 55 45 30 NO 
Smad7   1.5 95 60 45 38 YES 
Smad9   2.5 95 55 45 45 NO 
Tip60   2.5 95 55 45 45 NO 
Ube2a   2.5 95 55 45 30 NO 
!%%*!
Ube2b   2.5 95 55 45 30 NO 
Ube2c   2.5 95 55 45 30 NO 
Ube2d1   2.5 95 55 45 30 NO 
Ube2d2   2.5 95 55 45 30 NO 
Ube2d3   2.5 95 55 45 30 NO 
Ube2f   2.5 95 55 45 30 NO 
Ube2g1   2.5 95 55 45 30 NO 
Ube2h   2.5 95 55 45 30 NO 
Ube2i   2.5 95 55 45 26 NO 
Ube2j1   2.5 95 55 45 30 NO 
Ube2j2   2.5 95 55 45 30 NO 
Ube2k   2.5 95 55 45 30 NO 
Yb1    2.5 95 55 45 30 NO 
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7.5 APPENDIX E-Expressions of all candidate partner transcripts of SoxC 
transcription factors in murine kidney tissue at E13.5, E18.5 and P21 
 
 
Figure 16. Expressions of all candidate partner transcripts of SoxC transcription factors 
in murine kidney tissue at E13.5, E18.5 and P21. N=4. Biological replicate 1 (Bio 1), 
Biological replicate 2(Bio 2), Biological replicate 3(Bio 3), Biological replicate 4(Bio 
4). 
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7.6 APPENDIX F- The fold change of the gel electrophoresis band pixel 
intensities of each candidate SoxC signaling partner`s expression at E13.5 to 
P21 in mouse kidney tissue, standard deviation and P-value 
Table 8. The fold change of the gel electrophoresis band pixel intensities of each 
candidate SoxC signaling partner`s expression at E13.5 to P21 in mouse kidney tissue, 
standard deviation and P-value. (n=3, P-value from the Student’s t-test)   
Gene Fold change of 
E13.5/P21 
Standard 
deviation  
P-Value  
Dlx3 807 537.0443805 0.023958241 
Dlx6 766.5 393.1560335 0.008038295 
Dlx2 633.75 67.55923327 0.000000149 
Pax7 493 273.0946112 0.011323653 
Dlx5 452.5 193.0224512 0.003402246 
Pax4 293.25 97.31863473 0.000959453 
Pax6 247.25 92.57564475 0.001795226 
Pou4f3 242.75 220.6647155 0.070966452 
Col2a1 229.25 205.1249619 0.067686227 
Pax3 224 67.50308635 0.000578336 
Pou4f2 113 169.5464538 0.234590483 
Cxxc4 107.3403456 203.7960713 0.33688384 
Dlx4 85.25 65.63218215 0.042486917 
Hdac9 57.61022727 54.28965631 0.08210903 
!%*-!
Pou3f2 50.5 31.87998327 0.020971577 
Hhex 25.6528481 44.91157593 0.314366638 
Egr3 24.08239273 44.61207381 0.340654227 
Pou5f1 8.952898551 17.36894849 0.395106866 
Ube2c 3.643703247 1.900049072 0.031880061 
Pou3f1 3.416903294 1.951084435 0.047967731 
Pou4f1 3.0289015 0.735789043 0.001493993 
Egr1 2.964151306 0.925549825 0.005414092 
Med18 2.72692667 0.421071657 0.000177063 
Myst1 2.442417372 0.513837017 0.001362833 
Ube2i 2.409187642 1.086919672 0.041046577 
Hoxb4 2.252016622 1.008275651 0.047580441 
Egr2 2.02975367 1.458968611 0.207758118 
Pou2f1 1.888799925 0.180584877 0.000063302 
Smad6 1.818421461 0.256597494 0.000697756 
Dlx1 1.812933814 0.857103466 0.106622303 
Med27 1.698042976 0.43947541 0.019155415 
Hdac8 1.600107138 0.577061664 0.082749467 
Sf1 1.549631094 0.15145819 0.000347785 
Med12 1.521343578 0.206366287 0.002327631 
!%*%!
Med4 1.498260042 0.068210069 0.000006455 
Ctbp2 1.475363373 0.481346435 0.095666153 
Smad9 1.450913155 0.410784525 0.070550248 
Myst4 1.446939082 0.367072702 0.05080527 
Smad3 1.413398554 0.44298057 0.111226222 
Hoxa6 1.411515184 0.426253953 0.101724939 
Med6 1.402278042 0.052589828 0.000004926 
Smad1 1.391409744 0.201431341 0.008111504 
Med23 1.368964827 0.12478066 0.001040469 
Mef2d 1.36518119 0.431839137 0.14173469 
Pou3f4 1.361111539 0.198022546 0.010742458 
Med1 1.347873158 0.390523353 0.125103739 
Med29 1.336901875 0.470954035 0.202461644 
Mef2b 1.305072846 0.491431837 0.260729223 
Hdac3 1.280220245 0.158994959 0.012444472 
Pou2f2 1.276400483 0.097777282 0.001314545 
Med15 1.271132288 0.249091843 0.072363373 
P53 1.270823518 0.178975643 0.023205955 
Ube2d1,28 1.256584809 0.163554828 0.02012919 
Pax2 1.249028439 0.084762125 0.001075986 
!%**!
Myst2 1.24485326 0.260423543 0.109090966 
Cbp 1.244442693 0.197197487 0.047859367 
Mef2a 1.231241463 0.075969696 0.000893679 
Hdac1 1.227717536 0.150859963 0.023429492 
Ube2j2 1.225725352 0.107691856 0.005736121 
Smad2 1.20906931 0.194772998 0.075438807 
Ube2d2 1.203750986 0.096889702 0.005649161 
Hdac7 1.199932688 0.187192394 0.076559505 
Med21 1.195034921 0.091570506 0.005322556 
Hoxd4 1.181314813 0.276046306 0.236955112 
Hdac10 1.179293238 0.251195089 0.203339901 
Smad4 1.167832745 0.117967616 0.029358054 
Hdac2 1.163928368 0.191558228 0.137828601 
Mef2c 1.163488636 0.173302362 0.108139109 
Myst3 1.161081707 0.181122709 0.125602027 
Med17 1.155120639 0.342947426 0.400523831 
Hoxa4 1.151706499 0.42543208 0.50251203 
Pou1f1 1.137709561 0.079348719 0.013287631 
Ube2j1 1.136876212 0.26537674 0.342053855 
Hoxa2 1.112988962 0.036124915 0.00077415 
!%*,!
Hdac5 1.111015152 0.199692806 0.308753874 
Ube2g1 1.11082565 0.181422805 0.267625232 
Ube2b 1.109785588 0.074868483 0.02619297 
Smad5 1.106475551 0.049734042 0.005195358 
Ep300 1.087412542 0.081169557 0.074710722 
Hnrnpk 1.079977774 0.109750023 0.195257903 
Ybx1 1.075187219 0.179721344 0.434808192 
Ube2k 1.06892745 0.081582035 0.142030952 
Maf1 1.060456384 0.068302101 0.127077513 
Med25 1.051921127 0.025317482 0.006345926 
Hoxa10 1.042984267 0.058085744 0.189360046 
Runx2 1.033433909 0.06687252 0.355949073 
Ube2a 1.027689398 0.174019351 0.76109313 
Ctbp1 1.021585015 0.070995143 0.565431946 
Nherf2 1.017249979 0.17116119 0.84691743 
Ube2h 1.011497504 0.262687978 0.933092845 
Runx1 1.009828354 0.079842898 0.813739345 
Ube2d3 1.008039639 0.107454305 0.885953262 
Cxxc5 1.007822274 0.056149691 0.789888405 
Otx2 1.007520293 0.187591009 0.938703462 
!%*&!
Hdac11 1.002654731 0.043158184 0.906106105 
Med30 1.000866358 0.045236025 0.970688056 
Smad7 1.000378473 0.430055777 0.998652695 
Tip60 0.99600028 0.049095226 0.875917201 
Runx3 0.992374933 0.066551694 0.826365675 
P73 0.948615998 0.122227451 0.432687304 
Med28 0.947117317 0.123315224 0.423997417 
Pou3f3 0.943184547 0.175065827 0.540323968 
Hdac6 0.926472806 0.082712398 0.12574159 
Ube2f 0.897346679 0.189684565 0.320662661 
Pax8 0.889559298 0.126544572 0.131509537 
P63 0.865123653 0.239535262 0.30311906 
Pgc1b 0.727934244 0.215602852 0.045057227 
Olig2 0.673326824 0.164609256 0.007374767 
Olig1 0.613969324 0.179123951 0.005036277 
Pgc1a 0.304919755 0.160219104 0.000129329 
Pax5 0.271535014 0.292185333 0.002486 
Pou2f3 0.268594971 0.301401553 0.002841939 
 
